<!DOCTYPE html>
<html prefix='og: http://ogp.me/ns#'>
<head>
<link href='../favicon.png' rel='icon' type='image/png'>
<link href='../assets/apple-touch-icon.png' rel='apple-touch-icon' sizes='72x72' type='image/png'>
<link href='trials.html' rel='canonical'>
<meta content='text/html;charset=utf-8' http-equiv='Content-Type'>
<meta content='IE=edge,chrome=1' http-equiv='X-UA-Compatible'>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-6.newrelic.com","errorBeacon":"bam.nr-data.net","licenseKey":"df7d6b7270","applicationID":"3316025","transactionName":"cl5cF0cLWlsDEEsHWF9FVw1BS0JFDwMIO0dQVlc=","queueTime":0,"applicationTime":931,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-515.min.js"}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function(n,t,e){function r(e){if(!t[e]){var o=t[e]={exports:{}};n[e][0].call(o.exports,function(t){var o=n[e][1][t];return r(o?o:t)},o,o.exports)}return t[e].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<e.length;o++)r(e[o]);return r}({QJf3ax:[function(n,t){function e(n){function t(t,e,a){n&&n(t,e,a),a||(a={});for(var u=c(t),f=u.length,s=i(a,o,r),p=0;f>p;p++)u[p].apply(s,e);return s}function a(n,t){f[n]=c(n).concat(t)}function c(n){return f[n]||[]}function u(){return e(t)}var f={};return{on:a,emit:t,create:u,listeners:c,_events:f}}function r(){return{}}var o="nr@context",i=n("gos");t.exports=e()},{gos:"7eSDFh"}],ee:[function(n,t){t.exports=n("QJf3ax")},{}],gos:[function(n,t){t.exports=n("7eSDFh")},{}],"7eSDFh":[function(n,t){function e(n,t,e){if(r.call(n,t))return n[t];var o=e();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(n,t,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return n[t]=o,o}var r=Object.prototype.hasOwnProperty;t.exports=e},{}],D5DuLP:[function(n,t){function e(n,t,e){return r.listeners(n).length?r.emit(n,t,e):(o[n]||(o[n]=[]),void o[n].push(t))}var r=n("ee").create(),o={};t.exports=e,e.ee=r,r.q=o},{ee:"QJf3ax"}],handle:[function(n,t){t.exports=n("D5DuLP")},{}],XL7HBI:[function(n,t){function e(n){var t=typeof n;return!n||"object"!==t&&"function"!==t?-1:n===window?0:i(n,o,function(){return r++})}var r=1,o="nr@id",i=n("gos");t.exports=e},{gos:"7eSDFh"}],id:[function(n,t){t.exports=n("XL7HBI")},{}],loader:[function(n,t){t.exports=n("G9z0Bl")},{}],G9z0Bl:[function(n,t){function e(){var n=v.info=NREUM.info;if(n&&n.licenseKey&&n.applicationID&&f&&f.body){c(d,function(t,e){t in n||(n[t]=e)}),v.proto="https"===l.split(":")[0]||n.sslForHttp?"https://":"http://",a("mark",["onload",i()]);var t=f.createElement("script");t.src=v.proto+n.agent,f.body.appendChild(t)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=n("handle"),c=n(1),u=window,f=u.document,s="addEventListener",p="attachEvent",l=(""+location).split("?")[0],d={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-515.min.js"},v=t.exports={offset:i(),origin:l,features:{}};f[s]?(f[s]("DOMContentLoaded",o,!1),u[s]("load",e,!1)):(f[p]("onreadystatechange",r),u[p]("onload",e)),a("mark",["firstbyte",i()])},{1:11,handle:"D5DuLP"}],11:[function(n,t){function e(n,t){var e=[],o="",i=0;for(o in n)r.call(n,o)&&(e[i]=t(o,n[o]),i+=1);return e}var r=Object.prototype.hasOwnProperty;t.exports=e},{}]},{},["G9z0Bl"]);</script>
<meta content='ycLJxifWV5TMCaeBV4zy1XzXAlxSn13YlTqZjZ4_GeQ' name='google-site-verification'>
<!-- / OG and Twitter Card meta data tags -->
<meta content="Clinical Trials for Sarcoma" property="og:description" />
<meta content="Clinical Trials for Sarcoma" property="twitter:description" />
<meta content="Clinical Trials for Sarcoma" property="og:title" />
<meta content="Clinical Trials for Sarcoma" property="twitter:title" />
<meta content="https://www.smartpatients.com/sarcoma/trials" property="og:url" />
<meta content="https://www.smartpatients.com/sarcoma/trials" property="twitter:url" />
<meta content="article" property="og:type" />
<meta content="article" property="twitter:type" />
<meta content="https://www.smartpatients.com/smart-patients-logo-200.png" property="og:image" />
<meta content="summary" property="twitter:card" />
<meta content="@smart_patients" property="twitter:site" />
<meta content="https://www.smartpatients.com/smart-patients-logo-200.png" property="twitter:image" />
<script>window.gon = {};gon.browser={"os":null,"platform":null,"browser":"SiteSucker","version":""};gon.selection=null;gon.privileges=[];</script>
<meta content="authenticity_token" name="csrf-param" />
<meta content="anHdzK0RV47A1fm+Cc5YWchDmz7Dd1CW3v8C5VSfjds=" name="csrf-token" />
<title>Clinical Trials for Sarcoma | Smart Patients</title>
<!--[if lt IE 10]>
<script src='https://html5shim.googlecode.com/svn/trunk/html5.js'></script>
<![endif]-->
<link href="../assets/application-d023587940a25f1311fac7be224dde01.css" media="all" rel="stylesheet" type="text/css" />
<link href="../assets/print/print-791dc2f04757964770191d5c923539c6.css" media="print" rel="stylesheet" type="text/css" />

<!--[if lt IE 10]>
<link href="/assets/ie/ie-fb3a9d11af866d1ad554b557627df8f6.css" media="all" rel="stylesheet" type="text/css" />
<![endif]-->
<!--[if lt IE 9]>
<link href="/assets/ie/ie8-b1f4d1991397313b50b84b7d76d6ba05.css" media="all" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="https://fonts.googleapis.com/css?family=Handlee%7CBitter:400,700" rel="stylesheet" type="text/css" />

</head>

<body class='not-logged-in'>
<script id='tag_template' type='text/x-handlebars-template'>
<p>
{{{description}}}
</p>
<p class='status_{{tag_name}}'></p>
<p class='tag_link'>
<img alt="Icon_favorite_selected" src="/assets/icon_favorite_selected-37a484115fc7df83408fabd97664140b.png" />
{{{follow_link}}}
</p>
<img alt="Spinner" class="spinner hidden" src="/assets/spinner-3f3b3866a7fa212b261a33db16ecbaf5.gif" />
<div class='topic-count'>
<a href='{{tag_path}}'>
{{{count}}}
</a>
</div>
</script>

<script id='interest_template' type='text/x-handlebars-template'>
<li class='interest' data-interest-id='{{id}}'>
<div class='outer'>
<div class='inner'>
{{{url}}}
{{{remove_link}}}
</div>
</div>
</li>
</script>

<script id='alert_template' type='text/x-handlebars-template'>
<div class='alert {{class}}'>
<button aria-hidden='true' class='close' data-dismiss='alert' type='button'>
x
</button>
<p>
{{message}}
</p>
</div>
</script>

<script id='alert_template_html' type='text/x-handlebars-template'>
<div class='alert {{class}}'>
<button aria-hidden='true' class='close' data-dismiss='alert' type='button'>
x
</button>
<p>
{{{message}}}
</p>
</div>
</script>

<script id='profile_popup_template' type='text/x-handlebars-template'><pre class='profile_popup'>{{ profile }}</pre><div class='instructions'>
{{ instructions }}
</div>
</script>

<script id='survey_rating_results_template' type='text/x-handlebars-template'>
<div class='rating-result'>
<div>
{{message}}
</div>
<div>
Your rating: {{user_rating}}
</div>
<div>
Average: {{average}}
</div>
<div>
Total # of votes: {{count}}
</div>
</div>
</script>

<script id='target_details_template' type='text/x-handlebars-template'>
<p>
{{name}} <span class="pill {{node_type}}">{{node_type}}</span>
<ul>
{{#each neighbors}}
<li>
{{this.name}} <span class="pill {{this.node_type}}">{{this.node_type}}</span>
</li>
{{/each}}
</ul>
</p>
</script>

<script id='trial_contact_message' type='text/x-handlebars-template'>
I'm interested in "{{{brief_title}}}"
Trial ID: {{trial_id}}
{{institution}}
{{address}}
Thank you in advance for contacting me to discuss this trial.
</script>

<script id='featured_quote_template' type='text/x-handlebars-template'>
<div class='testimonial quoted-snippet'>
{{trimString quote 250}}
</div>
{{#if attribution}}
<div class='signed'>
â€“ {{attribution}}
</div>
{{/if}}
</script>


<div class='container'>
<div class='navbar'>
<div class='navbar-inner'>
<div class='clearfix'>
<div class='row'>
<a href="../index.html" class="brand"><img alt="Smart-patients-logo-350" height="69" src="../assets/smart-patients-logo-350-bb0285894b87daf2798d6c0a81d0c51b.png" style="height: 69px" width="350" /></a>
<ul class='nav'>
</ul>

</div>
</div>
</div>
</div>
</div>

<div class='container' data-title='Clinical Trials for Sarcoma | Smart Patients' id='page'>
<div class='row'>
<div class='span2'></div>
<div class='span10 divider main'>
<div class='row'>
<div class='span7 messages'>

</div>
</div>
</div>
</div>
<div class='row'>
<div class='span12 divider main'>
<div class='row'>
<div class='span9 right-divider'>

<script id='trial_popover_template' type='text/x-handlebars-template'>
<ul>
{{ds}}
{{#each trials}}
<li>
{{#if this.link}}
<a class='trial_widget_links' data-intervention='{{../../../intervention}}' data-trial-id='{{this.id}}' href='{{this.link}}' target='_blank'>
{{this.id}}
{{#if this.text}}
({{this.text}})
{{/if}}
</a>
{{else}}
{{#if ../../source}}
<a href='/clinical-trials/{{this.id}}?source={{../../source}}' target='_blank'></a>
{{else}}
<a class='trial_widget_links' data-intervention='{{../../../intervention}}' data-trial-id='{{this.id}}' href='/clinical-trials/{{this.id}}' target='_blank'>
{{/if}}
{{this.id}}
{{#if this.text}}
({{this.text}})
{{/if}}
</a>
{{/if}}
<p>
{{trimString this.title 120}}
</p>
</li>
{{/each}}
</ul>
</script>



<div id='content-page'>
<div class='content-title'>
<h1>Clinical Trials for Sarcoma</h1>
</div>
<div class='content-main'>
<p>
Researchers around the world are working to develop new drugs for the treatment of sarcoma. These new treatments must go through a rigorous trial process, testing their safety and efficacy, before they are made available to the people who need them. Patients play a critical role in the development of new treatments through their participation in these clinical trials. Below are ongoing clinical trials for sarcoma.
</p>
<div class="selector"><span class="selected" data-condition-name="Adult Sarcoma" data-name="adult-sarcoma">Adult Sarcoma</span> | <span class="unselected" data-condition-name="Pediatric Sarcoma" data-name="pediatric-sarcoma">Pediatric Sarcoma</span></div><div class="trial-container"><div class="trial_table adult-sarcoma_table"><table class='adult-sarcoma' data-condition-name='Adult Sarcoma' id='trial-widget'>
<tr>
<th>
<div class='condition_name'>
Adult Sarcoma
</div>
</th>
<th>
<div class='big'>
92
</div>
<div class='th_label'>
phase 1
</div>
</th>
<th>
<div class='big'>
176
</div>
<div class='th_label'>
phase 2
</div>
</th>
<th>
<div class='big'>
35
</div>
<div class='th_label'>
phase 3
</div>
</th>
<th>
<div class='big'>
36
</div>
<div class='th_label'>
other*
</div>
</th>
<th>
<div class='big'>
339
</div>
<div class='th_label'>total</div>
</th>
</tr>
<tr class="subheader_0"><td colspan="6">Targeted Therapy</td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="ALK" data-id="adult-sarcoma" data-name="alk_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">ALK</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="ALK" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="ALK" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01524926&quot;,&quot;title&quot;:&quot;CREATE: Cross-tumoral Phase 2 With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="ALK" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="ALK" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="ALK" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01524926&quot;,&quot;title&quot;:&quot;CREATE: Cross-tumoral Phase 2 With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class="alk_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Crizotinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Crizotinib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Crizotinib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01524926&quot;,&quot;title&quot;:&quot;CREATE: Cross-tumoral Phase 2 With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Crizotinib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Crizotinib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Crizotinib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="BCR-ABL" data-id="adult-sarcoma" data-name="bcr-abl_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">BCR-ABL</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="BCR-ABL" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01643278&quot;,&quot;title&quot;:&quot;Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="BCR-ABL" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="BCR-ABL" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="BCR-ABL" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="BCR-ABL" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01643278&quot;,&quot;title&quot;:&quot;Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class="bcr-abl_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Dasatinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Dasatinib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01643278&quot;,&quot;title&quot;:&quot;Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Dasatinib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Dasatinib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Dasatinib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Dasatinib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="c-MET (MET)" data-id="adult-sarcoma" data-name="c-met-met_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">c-MET (MET)</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="c-MET (MET)" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01468922&quot;,&quot;title&quot;:&quot;Pazopanib and ARQ 197 for Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="c-MET (MET)" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="c-MET (MET)" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="c-MET (MET)" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="c-MET (MET)" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01468922&quot;,&quot;title&quot;:&quot;Pazopanib and ARQ 197 for Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class="c-met-met_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Tivantinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Tivantinib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01468922&quot;,&quot;title&quot;:&quot;Pazopanib and ARQ 197 for Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Tivantinib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Tivantinib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Tivantinib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Tivantinib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="CDK 4/6" data-id="adult-sarcoma" data-name="cdk-4-6_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CDK 4/6</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="CDK 4/6" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02255461&quot;,&quot;title&quot;:&quot;Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="CDK 4/6" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="CDK 4/6" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="CDK 4/6" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="CDK 4/6" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02255461&quot;,&quot;title&quot;:&quot;Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class="cdk-4-6_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Palbociclib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Palbociclib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02255461&quot;,&quot;title&quot;:&quot;Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Palbociclib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Palbociclib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Palbociclib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Palbociclib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="CTLA-4" data-id="adult-sarcoma" data-name="ctla-4_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CTLA-4</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="CTLA-4" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01643278&quot;,&quot;title&quot;:&quot;Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02210104&quot;,&quot;title&quot;:&quot;Adoptive Therapy Using Antigen-Specific CD4 T-Cells&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02261220&quot;,&quot;title&quot;:&quot;A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td data-content-name="sarcoma" data-intervention="CTLA-4" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="CTLA-4" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="CTLA-4" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="CTLA-4" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01643278&quot;,&quot;title&quot;:&quot;Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02210104&quot;,&quot;title&quot;:&quot;Adoptive Therapy Using Antigen-Specific CD4 T-Cells&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02261220&quot;,&quot;title&quot;:&quot;A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td></div></td></tr><tr class="ctla-4_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ipilimumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Ipilimumab" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01643278&quot;,&quot;title&quot;:&quot;Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02210104&quot;,&quot;title&quot;:&quot;Adoptive Therapy Using Antigen-Specific CD4 T-Cells&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td data-content-name="sarcoma" data-intervention="Ipilimumab" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Ipilimumab" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Ipilimumab" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Ipilimumab" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">2</td></div></td></tr><tr class="ctla-4_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Tremelimumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Tremelimumab" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02261220&quot;,&quot;title&quot;:&quot;A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Tremelimumab" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Tremelimumab" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Tremelimumab" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Tremelimumab" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Heat Shock Proteins" data-id="adult-sarcoma" data-name="heat-shock-proteins_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Heat Shock Proteins</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Heat Shock Proteins" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Heat Shock Proteins" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02008877&quot;,&quot;title&quot;:&quot;A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Heat Shock Proteins" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Heat Shock Proteins" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Heat Shock Proteins" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02008877&quot;,&quot;title&quot;:&quot;A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class="heat-shock-proteins_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ganetespib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Ganetespib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Ganetespib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02008877&quot;,&quot;title&quot;:&quot;A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Ganetespib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Ganetespib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Ganetespib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Histone deacetylase (HDAC/HDI)" data-id="adult-sarcoma" data-name="histone-deacetylase-hdac-hdi_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Histone deacetylase (HDAC/HDI)</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01005797&quot;,&quot;title&quot;:&quot;Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01638533&quot;,&quot;title&quot;:&quot;Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01010958&quot;,&quot;title&quot;:&quot;Adjuvant Valproate for High Grade Sarcomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td class="on phases" data-content-name="sarcoma" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01106872&quot;,&quot;title&quot;:&quot;Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01879085&quot;,&quot;title&quot;:&quot;Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="sarcoma" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01005797&quot;,&quot;title&quot;:&quot;Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01638533&quot;,&quot;title&quot;:&quot;Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01010958&quot;,&quot;title&quot;:&quot;Adjuvant Valproate for High Grade Sarcomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01106872&quot;,&quot;title&quot;:&quot;Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01879085&quot;,&quot;title&quot;:&quot;Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">6</td></div></td></tr><tr class="histone-deacetylase-hdac-hdi_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Panobinostat</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Panobinostat" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01005797&quot;,&quot;title&quot;:&quot;Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Panobinostat" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Panobinostat" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Panobinostat" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Panobinostat" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="histone-deacetylase-hdac-hdi_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Romidepsin</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Romidepsin" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01638533&quot;,&quot;title&quot;:&quot;Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Romidepsin" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Romidepsin" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Romidepsin" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Romidepsin" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="histone-deacetylase-hdac-hdi_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Valproic acid</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Valproic acid" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01010958&quot;,&quot;title&quot;:&quot;Adjuvant Valproate for High Grade Sarcomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Valproic acid" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01106872&quot;,&quot;title&quot;:&quot;Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="sarcoma" data-intervention="Valproic acid" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Valproic acid" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Valproic acid" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">3</td></div></td></tr><tr class="histone-deacetylase-hdac-hdi_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Vorinostat</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Vorinostat" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Vorinostat" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01879085&quot;,&quot;title&quot;:&quot;Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Vorinostat" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Vorinostat" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Vorinostat" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="MEK" data-id="adult-sarcoma" data-name="mek_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MEK</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="MEK" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01438554&quot;,&quot;title&quot;:&quot;Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="MEK" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01752569&quot;,&quot;title&quot;:&quot;A Study of Selumetinib in Patients With Kaposi&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="MEK" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="MEK" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="MEK" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01438554&quot;,&quot;title&quot;:&quot;Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01752569&quot;,&quot;title&quot;:&quot;A Study of Selumetinib in Patients With Kaposi&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class="mek_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Selumetinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Selumetinib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Selumetinib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01752569&quot;,&quot;title&quot;:&quot;A Study of Selumetinib in Patients With Kaposi&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Selumetinib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Selumetinib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Selumetinib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="mek_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Trametinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Trametinib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01438554&quot;,&quot;title&quot;:&quot;Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Trametinib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Trametinib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Trametinib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Trametinib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="mTOR" data-id="adult-sarcoma" data-name="mtor_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">mTOR</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="mTOR" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01353625&quot;,&quot;title&quot;:&quot;Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01522820&quot;,&quot;title&quot;:&quot;Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02142803&quot;,&quot;title&quot;:&quot;MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">4</td><td class="on phases" data-content-name="sarcoma" data-intervention="mTOR" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01216826&quot;,&quot;title&quot;:&quot;Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01661283&quot;,&quot;title&quot;:&quot;Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01842594&quot;,&quot;title&quot;:&quot;A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02008877&quot;,&quot;title&quot;:&quot;A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">4</td><td data-content-name="sarcoma" data-intervention="mTOR" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="mTOR" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02133183&quot;,&quot;title&quot;:&quot;TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="mTOR" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02133183&quot;,&quot;title&quot;:&quot;TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01353625&quot;,&quot;title&quot;:&quot;Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01522820&quot;,&quot;title&quot;:&quot;Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02142803&quot;,&quot;title&quot;:&quot;MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01216826&quot;,&quot;title&quot;:&quot;Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01661283&quot;,&quot;title&quot;:&quot;Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01842594&quot;,&quot;title&quot;:&quot;A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02008877&quot;,&quot;title&quot;:&quot;A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">9</td></div></td></tr><tr class="mtor_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CC-115</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="CC-115" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01353625&quot;,&quot;title&quot;:&quot;Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="CC-115" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="CC-115" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="CC-115" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="CC-115" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="mtor_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Everolimus</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Everolimus" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01522820&quot;,&quot;title&quot;:&quot;Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Everolimus" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01216826&quot;,&quot;title&quot;:&quot;Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01661283&quot;,&quot;title&quot;:&quot;Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="sarcoma" data-intervention="Everolimus" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Everolimus" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Everolimus" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">3</td></div></td></tr><tr class="mtor_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MLN0128</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="MLN0128" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02142803&quot;,&quot;title&quot;:&quot;MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="MLN0128" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="MLN0128" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="MLN0128" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02133183&quot;,&quot;title&quot;:&quot;TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="MLN0128" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">2</td></div></td></tr><tr class="mtor_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sirolimus</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Sirolimus" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Sirolimus" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01842594&quot;,&quot;title&quot;:&quot;A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02008877&quot;,&quot;title&quot;:&quot;A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="sarcoma" data-intervention="Sirolimus" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sirolimus" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sirolimus" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">3</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Multikinase inhibitors" data-id="adult-sarcoma" data-name="multikinase-inhibitors_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Multikinase inhibitors</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Multikinase inhibitors" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01916135&quot;,&quot;title&quot;:&quot;PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01438554&quot;,&quot;title&quot;:&quot;Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01468922&quot;,&quot;title&quot;:&quot;Pazopanib and ARQ 197 for Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01985295&quot;,&quot;title&quot;:&quot;Combined Modality Treatment of Sarcomas of the Extremities&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01005797&quot;,&quot;title&quot;:&quot;Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01518413&quot;,&quot;title&quot;:&quot;Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01498835&quot;,&quot;title&quot;:&quot;Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">7</td><td class="on phases" data-content-name="sarcoma" data-intervention="Multikinase inhibitors" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01140737&quot;,&quot;title&quot;:&quot;A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01979393&quot;,&quot;title&quot;:&quot;IRCI Gynae Sarcomas, High Grade Uterine Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02243605&quot;,&quot;title&quot;:&quot;Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01059656&quot;,&quot;title&quot;:&quot;Phase II Pazopanib Study in Advanced Dermatofibrosarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01392352&quot;,&quot;title&quot;:&quot;HYPAZ: Hypertension Induced by Pazopanib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01442662&quot;,&quot;title&quot;:&quot;Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01462630&quot;,&quot;title&quot;:&quot;Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01532687&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01543802&quot;,&quot;title&quot;:&quot;Study of Preoperative Therapy With Pazopanib (Votrient\u00ae) to Treat High-risk Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01593748&quot;,&quot;title&quot;:&quot;A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01692496&quot;,&quot;title&quot;:&quot;Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01719302&quot;,&quot;title&quot;:&quot;Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01759303&quot;,&quot;title&quot;:&quot;Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01861951&quot;,&quot;title&quot;:&quot;A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01975519&quot;,&quot;title&quot;:&quot;A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02113826&quot;,&quot;title&quot;:&quot;Pazopanib for Metastatic Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02207309&quot;,&quot;title&quot;:&quot;Pazopanib Maintenance Phase II&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02212015&quot;,&quot;title&quot;:&quot;Evaluation of Votrient in Angiosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02048371&quot;,&quot;title&quot;:&quot;A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02048722&quot;,&quot;title&quot;:&quot;Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01900743&quot;,&quot;title&quot;:&quot;Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00541840&quot;,&quot;title&quot;:&quot;Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00874874&quot;,&quot;title&quot;:&quot;Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02050919&quot;,&quot;title&quot;:&quot;Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00753727&quot;,&quot;title&quot;:&quot;Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391962&quot;,&quot;title&quot;:&quot;Sunitinib or Cediranib for Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">26</td><td class="on phases" data-content-name="sarcoma" data-intervention="Multikinase inhibitors" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02180867&quot;,&quot;title&quot;:&quot;Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Multikinase inhibitors" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01446809&quot;,&quot;title&quot;:&quot;Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Multikinase inhibitors" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01446809&quot;,&quot;title&quot;:&quot;Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01916135&quot;,&quot;title&quot;:&quot;PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01438554&quot;,&quot;title&quot;:&quot;Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01468922&quot;,&quot;title&quot;:&quot;Pazopanib and ARQ 197 for Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01985295&quot;,&quot;title&quot;:&quot;Combined Modality Treatment of Sarcomas of the Extremities&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01005797&quot;,&quot;title&quot;:&quot;Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01518413&quot;,&quot;title&quot;:&quot;Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01498835&quot;,&quot;title&quot;:&quot;Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01140737&quot;,&quot;title&quot;:&quot;A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01979393&quot;,&quot;title&quot;:&quot;IRCI Gynae Sarcomas, High Grade Uterine Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02243605&quot;,&quot;title&quot;:&quot;Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01059656&quot;,&quot;title&quot;:&quot;Phase II Pazopanib Study in Advanced Dermatofibrosarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01392352&quot;,&quot;title&quot;:&quot;HYPAZ: Hypertension Induced by Pazopanib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01442662&quot;,&quot;title&quot;:&quot;Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01462630&quot;,&quot;title&quot;:&quot;Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01532687&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01543802&quot;,&quot;title&quot;:&quot;Study of Preoperative Therapy With Pazopanib (Votrient\u00ae) to Treat High-risk Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01593748&quot;,&quot;title&quot;:&quot;A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01692496&quot;,&quot;title&quot;:&quot;Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01719302&quot;,&quot;title&quot;:&quot;Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01759303&quot;,&quot;title&quot;:&quot;Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01861951&quot;,&quot;title&quot;:&quot;A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01975519&quot;,&quot;title&quot;:&quot;A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02113826&quot;,&quot;title&quot;:&quot;Pazopanib for Metastatic Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02207309&quot;,&quot;title&quot;:&quot;Pazopanib Maintenance Phase II&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02212015&quot;,&quot;title&quot;:&quot;Evaluation of Votrient in Angiosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02048371&quot;,&quot;title&quot;:&quot;A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02048722&quot;,&quot;title&quot;:&quot;Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01900743&quot;,&quot;title&quot;:&quot;Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00541840&quot;,&quot;title&quot;:&quot;Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00874874&quot;,&quot;title&quot;:&quot;Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02050919&quot;,&quot;title&quot;:&quot;Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00753727&quot;,&quot;title&quot;:&quot;Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391962&quot;,&quot;title&quot;:&quot;Sunitinib or Cediranib for Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02180867&quot;,&quot;title&quot;:&quot;Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">35</td></div></td></tr><tr class="multikinase-inhibitors_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">[18f]-ski-249380</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="[18f]-ski-249380" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01916135&quot;,&quot;title&quot;:&quot;PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="[18f]-ski-249380" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="[18f]-ski-249380" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="[18f]-ski-249380" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="[18f]-ski-249380" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="multikinase-inhibitors_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Axitinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Axitinib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Axitinib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01140737&quot;,&quot;title&quot;:&quot;A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Axitinib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Axitinib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Axitinib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="multikinase-inhibitors_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cabozantinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Cabozantinib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Cabozantinib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01979393&quot;,&quot;title&quot;:&quot;IRCI Gynae Sarcomas, High Grade Uterine Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02243605&quot;,&quot;title&quot;:&quot;Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="sarcoma" data-intervention="Cabozantinib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Cabozantinib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Cabozantinib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">2</td></div></td></tr><tr class="multikinase-inhibitors_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Pazopanib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Pazopanib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01438554&quot;,&quot;title&quot;:&quot;Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01468922&quot;,&quot;title&quot;:&quot;Pazopanib and ARQ 197 for Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01985295&quot;,&quot;title&quot;:&quot;Combined Modality Treatment of Sarcomas of the Extremities&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td class="on phases" data-content-name="sarcoma" data-intervention="Pazopanib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01059656&quot;,&quot;title&quot;:&quot;Phase II Pazopanib Study in Advanced Dermatofibrosarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01392352&quot;,&quot;title&quot;:&quot;HYPAZ: Hypertension Induced by Pazopanib&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01442662&quot;,&quot;title&quot;:&quot;Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01462630&quot;,&quot;title&quot;:&quot;Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01532687&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01543802&quot;,&quot;title&quot;:&quot;Study of Preoperative Therapy With Pazopanib (Votrient\u00ae) to Treat High-risk Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01593748&quot;,&quot;title&quot;:&quot;A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01692496&quot;,&quot;title&quot;:&quot;Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01719302&quot;,&quot;title&quot;:&quot;Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01759303&quot;,&quot;title&quot;:&quot;Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01861951&quot;,&quot;title&quot;:&quot;A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01975519&quot;,&quot;title&quot;:&quot;A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02113826&quot;,&quot;title&quot;:&quot;Pazopanib for Metastatic Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02207309&quot;,&quot;title&quot;:&quot;Pazopanib Maintenance Phase II&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02212015&quot;,&quot;title&quot;:&quot;Evaluation of Votrient in Angiosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">15</td><td class="on phases" data-content-name="sarcoma" data-intervention="Pazopanib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02180867&quot;,&quot;title&quot;:&quot;Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Pazopanib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01446809&quot;,&quot;title&quot;:&quot;Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Pazopanib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">20</td></div></td></tr><tr class="multikinase-inhibitors_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Regorafenib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Regorafenib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Regorafenib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02048371&quot;,&quot;title&quot;:&quot;A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02048722&quot;,&quot;title&quot;:&quot;Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01900743&quot;,&quot;title&quot;:&quot;Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="sarcoma" data-intervention="Regorafenib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Regorafenib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Regorafenib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">3</td></div></td></tr><tr class="multikinase-inhibitors_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sorafenib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Sorafenib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01005797&quot;,&quot;title&quot;:&quot;Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01518413&quot;,&quot;title&quot;:&quot;Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="sarcoma" data-intervention="Sorafenib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00541840&quot;,&quot;title&quot;:&quot;Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00874874&quot;,&quot;title&quot;:&quot;Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02050919&quot;,&quot;title&quot;:&quot;Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="sarcoma" data-intervention="Sorafenib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sorafenib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sorafenib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">5</td></div></td></tr><tr class="multikinase-inhibitors_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sunitinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Sunitinib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01498835&quot;,&quot;title&quot;:&quot;Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Sunitinib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00753727&quot;,&quot;title&quot;:&quot;Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391962&quot;,&quot;title&quot;:&quot;Sunitinib or Cediranib for Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="sarcoma" data-intervention="Sunitinib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sunitinib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sunitinib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">3</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Other antibodies or immunologics" data-id="adult-sarcoma" data-name="other-antibodies-or-immunologics_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Other antibodies or immunologics</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Other antibodies or immunologics" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02107963&quot;,&quot;title&quot;:&quot;A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With Non-neuroblastoma, GD2+ Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00902044&quot;,&quot;title&quot;:&quot;Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02208362&quot;,&quot;title&quot;:&quot;Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00062868&quot;,&quot;title&quot;:&quot;LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02239861&quot;,&quot;title&quot;:&quot;TAA-SPECIFIC CTLS FOR SOLID TUMORS (TACTASOM)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02186509&quot;,&quot;title&quot;:&quot;Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01469975&quot;,&quot;title&quot;:&quot;First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00743496&quot;,&quot;title&quot;:&quot;A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01875601&quot;,&quot;title&quot;:&quot;NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02076620&quot;,&quot;title&quot;:&quot;L19TNF\u03b1 in Combination With Doxorubicin in Patients With Advanced Solid Tumours&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01922076&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01849146&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01339039&quot;,&quot;title&quot;:&quot;Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">14</td><td class="on phases" data-content-name="sarcoma" data-intervention="Other antibodies or immunologics" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02173093&quot;,&quot;title&quot;:&quot;Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01648348&quot;,&quot;title&quot;:&quot;Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01327612&quot;,&quot;title&quot;:&quot;Open Label Extension Study of Conatumumab and AMG 479&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02100891&quot;,&quot;title&quot;:&quot;Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02052648&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01590069&quot;,&quot;title&quot;:&quot;Aerosol IL-2 for Pulmonary Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02095132&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02101775&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00445965&quot;,&quot;title&quot;:&quot;Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02137564&quot;,&quot;title&quot;:&quot;Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01721577&quot;,&quot;title&quot;:&quot;Phase I/II Trial of the Safety, Tolerability, and Anti-tumor Efficacy of AXL1717 (Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01977677&quot;,&quot;title&quot;:&quot;Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01975519&quot;,&quot;title&quot;:&quot;A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">13</td><td data-content-name="sarcoma" data-intervention="Other antibodies or immunologics" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Other antibodies or immunologics" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02180698&quot;,&quot;title&quot;:&quot;TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Metastatic Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Other antibodies or immunologics" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02180698&quot;,&quot;title&quot;:&quot;TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Metastatic Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02107963&quot;,&quot;title&quot;:&quot;A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With Non-neuroblastoma, GD2+ Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00902044&quot;,&quot;title&quot;:&quot;Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02208362&quot;,&quot;title&quot;:&quot;Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00062868&quot;,&quot;title&quot;:&quot;LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02239861&quot;,&quot;title&quot;:&quot;TAA-SPECIFIC CTLS FOR SOLID TUMORS (TACTASOM)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02186509&quot;,&quot;title&quot;:&quot;Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01469975&quot;,&quot;title&quot;:&quot;First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00743496&quot;,&quot;title&quot;:&quot;A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01875601&quot;,&quot;title&quot;:&quot;NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02076620&quot;,&quot;title&quot;:&quot;L19TNF\u03b1 in Combination With Doxorubicin in Patients With Advanced Solid Tumours&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01922076&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01849146&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01339039&quot;,&quot;title&quot;:&quot;Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02173093&quot;,&quot;title&quot;:&quot;Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01648348&quot;,&quot;title&quot;:&quot;Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01327612&quot;,&quot;title&quot;:&quot;Open Label Extension Study of Conatumumab and AMG 479&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02100891&quot;,&quot;title&quot;:&quot;Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02052648&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01590069&quot;,&quot;title&quot;:&quot;Aerosol IL-2 for Pulmonary Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02095132&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02101775&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00445965&quot;,&quot;title&quot;:&quot;Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02137564&quot;,&quot;title&quot;:&quot;Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01721577&quot;,&quot;title&quot;:&quot;Phase I/II Trial of the Safety, Tolerability, and Anti-tumor Efficacy of AXL1717 (Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01977677&quot;,&quot;title&quot;:&quot;Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01975519&quot;,&quot;title&quot;:&quot;A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">28</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Activated T Cells</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Activated T Cells" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02107963&quot;,&quot;title&quot;:&quot;A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With Non-neuroblastoma, GD2+ Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00902044&quot;,&quot;title&quot;:&quot;Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02208362&quot;,&quot;title&quot;:&quot;Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00062868&quot;,&quot;title&quot;:&quot;LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02239861&quot;,&quot;title&quot;:&quot;TAA-SPECIFIC CTLS FOR SOLID TUMORS (TACTASOM)&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">5</td><td class="on phases" data-content-name="sarcoma" data-intervention="Activated T Cells" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02173093&quot;,&quot;title&quot;:&quot;Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Activated T Cells" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Activated T Cells" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Activated T Cells" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">6</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Alemtuzumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Alemtuzumab" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Alemtuzumab" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Alemtuzumab" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Alemtuzumab" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Alemtuzumab" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Alisertib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Alisertib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02186509&quot;,&quot;title&quot;:&quot;Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Alisertib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Alisertib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Alisertib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Alisertib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">anti-endoglin monoclonal antibody trc105</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="anti-endoglin monoclonal antibody trc105" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="anti-endoglin monoclonal antibody trc105" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01648348&quot;,&quot;title&quot;:&quot;Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="anti-endoglin monoclonal antibody trc105" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="anti-endoglin monoclonal antibody trc105" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="anti-endoglin monoclonal antibody trc105" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Conatumumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Conatumumab" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Conatumumab" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01327612&quot;,&quot;title&quot;:&quot;Open Label Extension Study of Conatumumab and AMG 479&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Conatumumab" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Conatumumab" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Conatumumab" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Frizzled Homolog 10</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Frizzled Homolog 10" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01469975&quot;,&quot;title&quot;:&quot;First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Frizzled Homolog 10" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Frizzled Homolog 10" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Frizzled Homolog 10" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Frizzled Homolog 10" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ganitumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Ganitumab" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Ganitumab" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01327612&quot;,&quot;title&quot;:&quot;Open Label Extension Study of Conatumumab and AMG 479&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Ganitumab" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Ganitumab" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Ganitumab" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Haploidentical Transplant and Donor Natural Killer Cells</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Haploidentical Transplant and Donor Natural Killer Cells" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Haploidentical Transplant and Donor Natural Killer Cells" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02100891&quot;,&quot;title&quot;:&quot;Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Haploidentical Transplant and Donor Natural Killer Cells" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Haploidentical Transplant and Donor Natural Killer Cells" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Haploidentical Transplant and Donor Natural Killer Cells" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Humanized Anti-GD2 Antibody</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Humanized Anti-GD2 Antibody" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00743496&quot;,&quot;title&quot;:&quot;A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Humanized Anti-GD2 Antibody" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Humanized Anti-GD2 Antibody" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Humanized Anti-GD2 Antibody" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Humanized Anti-GD2 Antibody" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">IDO Inhibitor</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="IDO Inhibitor" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="IDO Inhibitor" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02052648&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="IDO Inhibitor" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="IDO Inhibitor" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="IDO Inhibitor" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Interleukin-2</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Interleukin-2" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01875601&quot;,&quot;title&quot;:&quot;NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Interleukin-2" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01590069&quot;,&quot;title&quot;:&quot;Aerosol IL-2 for Pulmonary Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Interleukin-2" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Interleukin-2" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Interleukin-2" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">2</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">L19TNF-alpha</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="L19TNF-alpha" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02076620&quot;,&quot;title&quot;:&quot;L19TNF\u03b1 in Combination With Doxorubicin in Patients With Advanced Solid Tumours&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="L19TNF-alpha" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="L19TNF-alpha" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="L19TNF-alpha" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="L19TNF-alpha" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MK-1775</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="MK-1775" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01922076&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01849146&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="sarcoma" data-intervention="MK-1775" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02095132&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02101775&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00445965&quot;,&quot;title&quot;:&quot;Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="sarcoma" data-intervention="MK-1775" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="MK-1775" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="MK-1775" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">5</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PF-03084014</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="PF-03084014" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="PF-03084014" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02137564&quot;,&quot;title&quot;:&quot;Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="PF-03084014" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="PF-03084014" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="PF-03084014" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Picropodophyllin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Picropodophyllin" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Picropodophyllin" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01721577&quot;,&quot;title&quot;:&quot;Phase I/II Trial of the Safety, Tolerability, and Anti-tumor Efficacy of AXL1717 (Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Picropodophyllin" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Picropodophyllin" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Picropodophyllin" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Plerixifor</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Plerixifor" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01339039&quot;,&quot;title&quot;:&quot;Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Plerixifor" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01977677&quot;,&quot;title&quot;:&quot;Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Plerixifor" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Plerixifor" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Plerixifor" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">2</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">tlr4 agonist gla-se</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="tlr4 agonist gla-se" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="tlr4 agonist gla-se" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="tlr4 agonist gla-se" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="tlr4 agonist gla-se" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02180698&quot;,&quot;title&quot;:&quot;TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Metastatic Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="tlr4 agonist gla-se" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">TRC105</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="TRC105" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="TRC105" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01975519&quot;,&quot;title&quot;:&quot;A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="TRC105" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="TRC105" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="TRC105" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="PARP" data-id="adult-sarcoma" data-name="parp_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PARP</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="PARP" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02044120&quot;,&quot;title&quot;:&quot;ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01858168&quot;,&quot;title&quot;:&quot;Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00989651&quot;,&quot;title&quot;:&quot;Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td class="on phases" data-content-name="sarcoma" data-intervention="PARP" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02116777&quot;,&quot;title&quot;:&quot;BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01514201&quot;,&quot;title&quot;:&quot;Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td class="on phases" data-content-name="sarcoma" data-intervention="PARP" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02152982&quot;,&quot;title&quot;:&quot;Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="PARP" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="PARP" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02044120&quot;,&quot;title&quot;:&quot;ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01858168&quot;,&quot;title&quot;:&quot;Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00989651&quot;,&quot;title&quot;:&quot;Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02116777&quot;,&quot;title&quot;:&quot;BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01514201&quot;,&quot;title&quot;:&quot;Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02152982&quot;,&quot;title&quot;:&quot;Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">6</td></div></td></tr><tr class="parp_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">BMN-673</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="BMN-673" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="BMN-673" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02116777&quot;,&quot;title&quot;:&quot;BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="BMN-673" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="BMN-673" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="BMN-673" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="parp_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Niraparib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Niraparib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02044120&quot;,&quot;title&quot;:&quot;ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Niraparib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Niraparib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Niraparib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Niraparib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="parp_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Olaparib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Olaparib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01858168&quot;,&quot;title&quot;:&quot;Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Olaparib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Olaparib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Olaparib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Olaparib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="parp_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Veliparib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Veliparib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00989651&quot;,&quot;title&quot;:&quot;Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Veliparib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01514201&quot;,&quot;title&quot;:&quot;Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Veliparib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02152982&quot;,&quot;title&quot;:&quot;Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Veliparib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Veliparib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">3</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="PD-L1/PD-1" data-id="adult-sarcoma" data-name="pd-l1-pd-1_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PD-L1/PD-1</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="PD-L1/PD-1" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02261220&quot;,&quot;title&quot;:&quot;A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="PD-L1/PD-1" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="PD-L1/PD-1" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="PD-L1/PD-1" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="PD-L1/PD-1" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02261220&quot;,&quot;title&quot;:&quot;A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class="pd-l1-pd-1_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MEDI4736</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="MEDI4736" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02261220&quot;,&quot;title&quot;:&quot;A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="MEDI4736" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="MEDI4736" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="MEDI4736" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="MEDI4736" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="VEGF" data-id="adult-sarcoma" data-name="vegf_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">VEGF</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="VEGF" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00989651&quot;,&quot;title&quot;:&quot;Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01339039&quot;,&quot;title&quot;:&quot;Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01746238&quot;,&quot;title&quot;:&quot;Bevacizumab/Doxorubicin/Radiation for Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02142803&quot;,&quot;title&quot;:&quot;MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">4</td><td class="on phases" data-content-name="sarcoma" data-intervention="VEGF" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00356031&quot;,&quot;title&quot;:&quot;Bevacizumab and Radiation Therapy for Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00923936&quot;,&quot;title&quot;:&quot;Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01106872&quot;,&quot;title&quot;:&quot;Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01149850&quot;,&quot;title&quot;:&quot;Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217437&quot;,&quot;title&quot;:&quot;Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01296815&quot;,&quot;title&quot;:&quot;Intralesional Bevacizumab for Treating AIDS-associated Kaposi\u00b4s Sarcoma of the Larynx, Pharynx and Oral Cavity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01327612&quot;,&quot;title&quot;:&quot;Open Label Extension Study of Conatumumab and AMG 479&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01492673&quot;,&quot;title&quot;:&quot;Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing&#x27;s Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01498328&quot;,&quot;title&quot;:&quot;A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01648348&quot;,&quot;title&quot;:&quot;Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01661283&quot;,&quot;title&quot;:&quot;Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01730950&quot;,&quot;title&quot;:&quot;Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01814813&quot;,&quot;title&quot;:&quot;Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01894061&quot;,&quot;title&quot;:&quot;NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01903330&quot;,&quot;title&quot;:&quot;ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01337401&quot;,&quot;title&quot;:&quot;A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391962&quot;,&quot;title&quot;:&quot;Sunitinib or Cediranib for Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">18</td><td data-content-name="sarcoma" data-intervention="VEGF" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="VEGF" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01189643&quot;,&quot;title&quot;:&quot;Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="VEGF" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01189643&quot;,&quot;title&quot;:&quot;Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00989651&quot;,&quot;title&quot;:&quot;Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01339039&quot;,&quot;title&quot;:&quot;Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01746238&quot;,&quot;title&quot;:&quot;Bevacizumab/Doxorubicin/Radiation for Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02142803&quot;,&quot;title&quot;:&quot;MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00356031&quot;,&quot;title&quot;:&quot;Bevacizumab and Radiation Therapy for Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00923936&quot;,&quot;title&quot;:&quot;Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01106872&quot;,&quot;title&quot;:&quot;Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01149850&quot;,&quot;title&quot;:&quot;Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217437&quot;,&quot;title&quot;:&quot;Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01296815&quot;,&quot;title&quot;:&quot;Intralesional Bevacizumab for Treating AIDS-associated Kaposi\u00b4s Sarcoma of the Larynx, Pharynx and Oral Cavity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01327612&quot;,&quot;title&quot;:&quot;Open Label Extension Study of Conatumumab and AMG 479&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01492673&quot;,&quot;title&quot;:&quot;Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing&#x27;s Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01498328&quot;,&quot;title&quot;:&quot;A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01648348&quot;,&quot;title&quot;:&quot;Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01661283&quot;,&quot;title&quot;:&quot;Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01730950&quot;,&quot;title&quot;:&quot;Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01814813&quot;,&quot;title&quot;:&quot;Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01894061&quot;,&quot;title&quot;:&quot;NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01903330&quot;,&quot;title&quot;:&quot;ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01337401&quot;,&quot;title&quot;:&quot;A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391962&quot;,&quot;title&quot;:&quot;Sunitinib or Cediranib for Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">23</td></div></td></tr><tr class="vegf_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Bevacizumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Bevacizumab" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00989651&quot;,&quot;title&quot;:&quot;Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01339039&quot;,&quot;title&quot;:&quot;Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01746238&quot;,&quot;title&quot;:&quot;Bevacizumab/Doxorubicin/Radiation for Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02142803&quot;,&quot;title&quot;:&quot;MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">4</td><td class="on phases" data-content-name="sarcoma" data-intervention="Bevacizumab" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00356031&quot;,&quot;title&quot;:&quot;Bevacizumab and Radiation Therapy for Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00923936&quot;,&quot;title&quot;:&quot;Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01106872&quot;,&quot;title&quot;:&quot;Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01149850&quot;,&quot;title&quot;:&quot;Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217437&quot;,&quot;title&quot;:&quot;Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01296815&quot;,&quot;title&quot;:&quot;Intralesional Bevacizumab for Treating AIDS-associated Kaposi\u00b4s Sarcoma of the Larynx, Pharynx and Oral Cavity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01327612&quot;,&quot;title&quot;:&quot;Open Label Extension Study of Conatumumab and AMG 479&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01492673&quot;,&quot;title&quot;:&quot;Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing&#x27;s Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01498328&quot;,&quot;title&quot;:&quot;A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01648348&quot;,&quot;title&quot;:&quot;Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01661283&quot;,&quot;title&quot;:&quot;Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01730950&quot;,&quot;title&quot;:&quot;Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01814813&quot;,&quot;title&quot;:&quot;Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01894061&quot;,&quot;title&quot;:&quot;NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01903330&quot;,&quot;title&quot;:&quot;ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">16</td><td data-content-name="sarcoma" data-intervention="Bevacizumab" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Bevacizumab" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01189643&quot;,&quot;title&quot;:&quot;Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Bevacizumab" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">21</td></div></td></tr><tr class="vegf_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cediranib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Cediranib" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Cediranib" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01337401&quot;,&quot;title&quot;:&quot;A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391962&quot;,&quot;title&quot;:&quot;Sunitinib or Cediranib for Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="sarcoma" data-intervention="Cediranib" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Cediranib" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Cediranib" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="null">2</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Vaccines</td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Allogeneic Tumor Cell</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Allogeneic Tumor Cell" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01143545&quot;,&quot;title&quot;:&quot;Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Allogeneic Tumor Cell" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Allogeneic Tumor Cell" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Allogeneic Tumor Cell" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Allogeneic Tumor Cell" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01143545&quot;,&quot;title&quot;:&quot;Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Autologous Activated Natural Killer (NK) Cells</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous Activated Natural Killer (NK) Cells" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01875601&quot;,&quot;title&quot;:&quot;NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Autologous Activated Natural Killer (NK) Cells" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Autologous Activated Natural Killer (NK) Cells" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Autologous Activated Natural Killer (NK) Cells" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous Activated Natural Killer (NK) Cells" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01875601&quot;,&quot;title&quot;:&quot;NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Autologous CD4+ NY-ESO-1-Specific T Cells</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous CD4+ NY-ESO-1-Specific T Cells" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02210104&quot;,&quot;title&quot;:&quot;Adoptive Therapy Using Antigen-Specific CD4 T-Cells&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Autologous CD4+ NY-ESO-1-Specific T Cells" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Autologous CD4+ NY-ESO-1-Specific T Cells" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Autologous CD4+ NY-ESO-1-Specific T Cells" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous CD4+ NY-ESO-1-Specific T Cells" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02210104&quot;,&quot;title&quot;:&quot;Adoptive Therapy Using Antigen-Specific CD4 T-Cells&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Autologous Dendritic Cells</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous Dendritic Cells" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01803152&quot;,&quot;title&quot;:&quot;Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous Dendritic Cells" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01898663&quot;,&quot;title&quot;:&quot;DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With High-risk Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01883518&quot;,&quot;title&quot;:&quot;Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="sarcoma" data-intervention="Autologous Dendritic Cells" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous Dendritic Cells" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01957956&quot;,&quot;title&quot;:&quot;Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous Dendritic Cells" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01957956&quot;,&quot;title&quot;:&quot;Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01803152&quot;,&quot;title&quot;:&quot;Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01898663&quot;,&quot;title&quot;:&quot;DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With High-risk Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01883518&quot;,&quot;title&quot;:&quot;Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">4</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Autologous NY-ESO-1 Specific CD8+ T Cells</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous NY-ESO-1 Specific CD8+ T Cells" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01477021&quot;,&quot;title&quot;:&quot;Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Autologous NY-ESO-1 Specific CD8+ T Cells" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Autologous NY-ESO-1 Specific CD8+ T Cells" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Autologous NY-ESO-1 Specific CD8+ T Cells" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous NY-ESO-1 Specific CD8+ T Cells" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01477021&quot;,&quot;title&quot;:&quot;Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Autologous Tumor Cell Vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous Tumor Cell Vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01061840&quot;,&quot;title&quot;:&quot;Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Autologous Tumor Cell Vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Autologous Tumor Cell Vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Autologous Tumor Cell Vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous Tumor Cell Vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01061840&quot;,&quot;title&quot;:&quot;Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Cancer vaccine ERC1671</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Cancer vaccine ERC1671" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Cancer vaccine ERC1671" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01903330&quot;,&quot;title&quot;:&quot;ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Cancer vaccine ERC1671" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Cancer vaccine ERC1671" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Cancer vaccine ERC1671" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01903330&quot;,&quot;title&quot;:&quot;ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cytotoxic T Cells</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Cytotoxic T Cells" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01956084&quot;,&quot;title&quot;:&quot;Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01447056&quot;,&quot;title&quot;:&quot;Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td data-content-name="sarcoma" data-intervention="Cytotoxic T Cells" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Cytotoxic T Cells" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Cytotoxic T Cells" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Cytotoxic T Cells" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01956084&quot;,&quot;title&quot;:&quot;Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01447056&quot;,&quot;title&quot;:&quot;Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">DEC-205-ny-eso-1 fusion protein vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="DEC-205-ny-eso-1 fusion protein vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01522820&quot;,&quot;title&quot;:&quot;Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="DEC-205-ny-eso-1 fusion protein vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="DEC-205-ny-eso-1 fusion protein vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="DEC-205-ny-eso-1 fusion protein vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="DEC-205-ny-eso-1 fusion protein vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01522820&quot;,&quot;title&quot;:&quot;Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">DNX-2401 With Interferon Gamma (IFN-ÃŽ_)</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="DNX-2401 With Interferon Gamma (IFN-ÃŽ_)" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02197169&quot;,&quot;title&quot;:&quot;DNX-2401 With Interferon Gamma (IFN-\u03b3) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="DNX-2401 With Interferon Gamma (IFN-ÃŽ_)" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="DNX-2401 With Interferon Gamma (IFN-ÃŽ_)" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="DNX-2401 With Interferon Gamma (IFN-ÃŽ_)" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="DNX-2401 With Interferon Gamma (IFN-ÃŽ_)" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02197169&quot;,&quot;title&quot;:&quot;DNX-2401 With Interferon Gamma (IFN-\u03b3) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Epigenetically-Modified Autologous Tumor Cell</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Epigenetically-Modified Autologous Tumor Cell" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01341496&quot;,&quot;title&quot;:&quot;Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Epigenetically-Modified Autologous Tumor Cell" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Epigenetically-Modified Autologous Tumor Cell" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Epigenetically-Modified Autologous Tumor Cell" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Epigenetically-Modified Autologous Tumor Cell" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01341496&quot;,&quot;title&quot;:&quot;Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Genetically Engineered HSV-1</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Genetically Engineered HSV-1" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02062827&quot;,&quot;title&quot;:&quot;Genetically Engineered HSV-1 Phase 1 Study&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Genetically Engineered HSV-1" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Genetically Engineered HSV-1" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Genetically Engineered HSV-1" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Genetically Engineered HSV-1" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02062827&quot;,&quot;title&quot;:&quot;Genetically Engineered HSV-1 Phase 1 Study&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">H1299 lysate vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="H1299 lysate vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="H1299 lysate vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02054104&quot;,&quot;title&quot;:&quot;Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="H1299 lysate vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="H1299 lysate vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="H1299 lysate vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02054104&quot;,&quot;title&quot;:&quot;Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Heat Shock Protein-Peptide Complex-96 (HSPPC-96)</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Heat Shock Protein-Peptide Complex-96 (HSPPC-96)" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Heat Shock Protein-Peptide Complex-96 (HSPPC-96)" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01814813&quot;,&quot;title&quot;:&quot;Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Heat Shock Protein-Peptide Complex-96 (HSPPC-96)" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Heat Shock Protein-Peptide Complex-96 (HSPPC-96)" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Heat Shock Protein-Peptide Complex-96 (HSPPC-96)" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01814813&quot;,&quot;title&quot;:&quot;Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">ID-LV305</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="ID-LV305" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02122861&quot;,&quot;title&quot;:&quot;A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="ID-LV305" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="ID-LV305" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="ID-LV305" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="ID-LV305" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02122861&quot;,&quot;title&quot;:&quot;A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">New castle disease virus</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="New castle disease virus" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="New castle disease virus" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01174537&quot;,&quot;title&quot;:&quot;New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="New castle disease virus" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="New castle disease virus" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="New castle disease virus" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01174537&quot;,&quot;title&quot;:&quot;New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">NY-ESO-1 Specific T Cells</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="NY-ESO-1 Specific T Cells" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01343043&quot;,&quot;title&quot;:&quot;A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02059850&quot;,&quot;title&quot;:&quot;NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02015416&quot;,&quot;title&quot;:&quot;A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td><td data-content-name="sarcoma" data-intervention="NY-ESO-1 Specific T Cells" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="NY-ESO-1 Specific T Cells" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="NY-ESO-1 Specific T Cells" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="NY-ESO-1 Specific T Cells" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01343043&quot;,&quot;title&quot;:&quot;A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02059850&quot;,&quot;title&quot;:&quot;NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02015416&quot;,&quot;title&quot;:&quot;A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">3</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Oncolytic HSV-1716</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Oncolytic HSV-1716" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02031965&quot;,&quot;title&quot;:&quot;Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Oncolytic HSV-1716" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Oncolytic HSV-1716" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Oncolytic HSV-1716" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Oncolytic HSV-1716" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02031965&quot;,&quot;title&quot;:&quot;Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="vaccine" height="24" src="../assets/icon-vaccine-8d1090fa19fbda7c23132b17cfc24e31.png" width="24" /><span class="intervention">Personalized NeoAntigen Cancer Vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Personalized NeoAntigen Cancer Vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02287428&quot;,&quot;title&quot;:&quot;Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Personalized NeoAntigen Cancer Vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Personalized NeoAntigen Cancer Vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Personalized NeoAntigen Cancer Vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Personalized NeoAntigen Cancer Vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02287428&quot;,&quot;title&quot;:&quot;Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Rindopepimut</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Rindopepimut" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Rindopepimut" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01498328&quot;,&quot;title&quot;:&quot;A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Rindopepimut" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Rindopepimut" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Rindopepimut" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01498328&quot;,&quot;title&quot;:&quot;A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="procedure" height="24" src="../assets/icon-procedure-53a976ab34598c312e7a319406d457ee.png" width="24" /><span class="intervention">Tumor Adoptive T Cell Therapy</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Tumor Adoptive T Cell Therapy" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Tumor Adoptive T Cell Therapy" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01326104&quot;,&quot;title&quot;:&quot;Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Tumor Adoptive T Cell Therapy" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Tumor Adoptive T Cell Therapy" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Tumor Adoptive T Cell Therapy" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01326104&quot;,&quot;title&quot;:&quot;Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Chemotherapy, Radiation, &amp; Surgery</td></tr><tr class=""><td><div><img alt="procedure" height="24" src="../assets/icon-procedure-53a976ab34598c312e7a319406d457ee.png" width="24" /><span class="intervention">Chemotherapy</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Chemotherapy" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01803152&quot;,&quot;title&quot;:&quot;Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00734682&quot;,&quot;title&quot;:&quot;A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00989651&quot;,&quot;title&quot;:&quot;Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01014598&quot;,&quot;title&quot;:&quot;Cisplatin in Treating Patients With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01143545&quot;,&quot;title&quot;:&quot;Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01375699&quot;,&quot;title&quot;:&quot;Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01426633&quot;,&quot;title&quot;:&quot;Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01746238&quot;,&quot;title&quot;:&quot;Bevacizumab/Doxorubicin/Radiation for Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01849146&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01858168&quot;,&quot;title&quot;:&quot;Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02013336&quot;,&quot;title&quot;:&quot;Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02014337&quot;,&quot;title&quot;:&quot;Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02094625&quot;,&quot;title&quot;:&quot;NAC to Prevent Cisplatin-induced Hearing Loss&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02164097&quot;,&quot;title&quot;:&quot;ODSH + ICE Chemotherapy in Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02168270&quot;,&quot;title&quot;:&quot;Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02223052&quot;,&quot;title&quot;:&quot;CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">16</td><td class="on phases" data-content-name="sarcoma" data-intervention="Chemotherapy" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00179816&quot;,&quot;title&quot;:&quot;Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00180947&quot;,&quot;title&quot;:&quot;Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00217607&quot;,&quot;title&quot;:&quot;Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00227669&quot;,&quot;title&quot;:&quot;Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00790244&quot;,&quot;title&quot;:&quot;A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00823797&quot;,&quot;title&quot;:&quot;Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00905658&quot;,&quot;title&quot;:&quot;Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00918489&quot;,&quot;title&quot;:&quot;Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00923936&quot;,&quot;title&quot;:&quot;Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00936052&quot;,&quot;title&quot;:&quot;Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00936156&quot;,&quot;title&quot;:&quot;Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00978471&quot;,&quot;title&quot;:&quot;Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01104298&quot;,&quot;title&quot;:&quot;Clinical Trial Of Doxorubicin Versus Trabectedin Plus Doxorubicin In The First Line Treatment Of Patients With Advanced Non Operable And/Or Metastatic Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01149850&quot;,&quot;title&quot;:&quot;Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01192633&quot;,&quot;title&quot;:&quot;Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217437&quot;,&quot;title&quot;:&quot;Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01303094&quot;,&quot;title&quot;:&quot;Continuing vs Intermittent Trabectedin-regimen in Patients With Advanced Soft Tissue Sarcoma Experiencing Response or Stable Disease After the 6th Cycle&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01380275&quot;,&quot;title&quot;:&quot;Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01492673&quot;,&quot;title&quot;:&quot;Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing&#x27;s Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01495598&quot;,&quot;title&quot;:&quot;Pomalidomide for Kaposi Sarcoma in People With or Without HIV&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01532687&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01610570&quot;,&quot;title&quot;:&quot;Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01650090&quot;,&quot;title&quot;:&quot;Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696669&quot;,&quot;title&quot;:&quot;Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing&#x27;s Sarcoma in Children and Young Adults&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01716689&quot;,&quot;title&quot;:&quot;Clinical Study of Metronomic Oral Cyclophosphamide in Patients With Advanced Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01719302&quot;,&quot;title&quot;:&quot;Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01822275&quot;,&quot;title&quot;:&quot;Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01848457&quot;,&quot;title&quot;:&quot;Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01864109&quot;,&quot;title&quot;:&quot;Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871766&quot;,&quot;title&quot;:&quot;Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01879085&quot;,&quot;title&quot;:&quot;Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01913652&quot;,&quot;title&quot;:&quot;Ph II Cabazitaxel/Ifosfamide DD Liposarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01946529&quot;,&quot;title&quot;:&quot;Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01977677&quot;,&quot;title&quot;:&quot;Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01987102&quot;,&quot;title&quot;:&quot;Investigation of [6R] 5,10-methylenetetrahydrofolate as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02022358&quot;,&quot;title&quot;:&quot;Will the Use of Glucarpidase After Methotrexate Treatment Allow More Patients With Bone Sarcoma to Have Fewer Side Effects and Receive Subsequent Chemotherapy on Time?&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02029430&quot;,&quot;title&quot;:&quot;A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02050919&quot;,&quot;title&quot;:&quot;Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02052648&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02097238&quot;,&quot;title&quot;:&quot;Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02235701&quot;,&quot;title&quot;:&quot;Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02247544&quot;,&quot;title&quot;:&quot;Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02249702&quot;,&quot;title&quot;:&quot;Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02249949&quot;,&quot;title&quot;:&quot;Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients With Previously Treated, Unresectable Myxoid Liposarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02255110&quot;,&quot;title&quot;:&quot;A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02267083&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02273583&quot;,&quot;title&quot;:&quot;Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02275286&quot;,&quot;title&quot;:&quot;Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">48</td><td class="on phases" data-content-name="sarcoma" data-intervention="Chemotherapy" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00162721&quot;,&quot;title&quot;:&quot;The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00210665&quot;,&quot;title&quot;:&quot;A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00334854&quot;,&quot;title&quot;:&quot;Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00379457&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00392327&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00691236&quot;,&quot;title&quot;:&quot;Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00876031&quot;,&quot;title&quot;:&quot;Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00987636&quot;,&quot;title&quot;:&quot;Study in Localized and Disseminated Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01231906&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01459484&quot;,&quot;title&quot;:&quot;ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01533207&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01692678&quot;,&quot;title&quot;:&quot;A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01987596&quot;,&quot;title&quot;:&quot;Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02049905&quot;,&quot;title&quot;:&quot;Phase 3 Study to Treat Patients With Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02063022&quot;,&quot;title&quot;:&quot;Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02099396&quot;,&quot;title&quot;:&quot;A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">17</td><td class="on phases" data-content-name="sarcoma" data-intervention="Chemotherapy" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00001686&quot;,&quot;title&quot;:&quot;Evaluation, Treatment, and Natural History of Children With Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01189643&quot;,&quot;title&quot;:&quot;Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01367301&quot;,&quot;title&quot;:&quot;Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01661400&quot;,&quot;title&quot;:&quot;Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01669369&quot;,&quot;title&quot;:&quot;Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01795430&quot;,&quot;title&quot;:&quot;Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01958580&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery&quot;,&quot;phase&quot;:&quot;other&quot;}]">7</td><td class="on phases" data-content-name="sarcoma" data-intervention="Chemotherapy" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00001686&quot;,&quot;title&quot;:&quot;Evaluation, Treatment, and Natural History of Children With Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01189643&quot;,&quot;title&quot;:&quot;Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01367301&quot;,&quot;title&quot;:&quot;Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01661400&quot;,&quot;title&quot;:&quot;Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01669369&quot;,&quot;title&quot;:&quot;Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01795430&quot;,&quot;title&quot;:&quot;Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01958580&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01803152&quot;,&quot;title&quot;:&quot;Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00734682&quot;,&quot;title&quot;:&quot;A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00989651&quot;,&quot;title&quot;:&quot;Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01014598&quot;,&quot;title&quot;:&quot;Cisplatin in Treating Patients With Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01143545&quot;,&quot;title&quot;:&quot;Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01375699&quot;,&quot;title&quot;:&quot;Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01426633&quot;,&quot;title&quot;:&quot;Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01746238&quot;,&quot;title&quot;:&quot;Bevacizumab/Doxorubicin/Radiation for Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01849146&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01858168&quot;,&quot;title&quot;:&quot;Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02013336&quot;,&quot;title&quot;:&quot;Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02014337&quot;,&quot;title&quot;:&quot;Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02094625&quot;,&quot;title&quot;:&quot;NAC to Prevent Cisplatin-induced Hearing Loss&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02164097&quot;,&quot;title&quot;:&quot;ODSH + ICE Chemotherapy in Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02168270&quot;,&quot;title&quot;:&quot;Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02223052&quot;,&quot;title&quot;:&quot;CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00179816&quot;,&quot;title&quot;:&quot;Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00180947&quot;,&quot;title&quot;:&quot;Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00217607&quot;,&quot;title&quot;:&quot;Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00227669&quot;,&quot;title&quot;:&quot;Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00790244&quot;,&quot;title&quot;:&quot;A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00823797&quot;,&quot;title&quot;:&quot;Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00905658&quot;,&quot;title&quot;:&quot;Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00918489&quot;,&quot;title&quot;:&quot;Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00923936&quot;,&quot;title&quot;:&quot;Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00936052&quot;,&quot;title&quot;:&quot;Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00936156&quot;,&quot;title&quot;:&quot;Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00978471&quot;,&quot;title&quot;:&quot;Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01104298&quot;,&quot;title&quot;:&quot;Clinical Trial Of Doxorubicin Versus Trabectedin Plus Doxorubicin In The First Line Treatment Of Patients With Advanced Non Operable And/Or Metastatic Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01149850&quot;,&quot;title&quot;:&quot;Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01192633&quot;,&quot;title&quot;:&quot;Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217437&quot;,&quot;title&quot;:&quot;Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01303094&quot;,&quot;title&quot;:&quot;Continuing vs Intermittent Trabectedin-regimen in Patients With Advanced Soft Tissue Sarcoma Experiencing Response or Stable Disease After the 6th Cycle&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01380275&quot;,&quot;title&quot;:&quot;Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01492673&quot;,&quot;title&quot;:&quot;Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing&#x27;s Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01495598&quot;,&quot;title&quot;:&quot;Pomalidomide for Kaposi Sarcoma in People With or Without HIV&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01532687&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01610570&quot;,&quot;title&quot;:&quot;Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01650090&quot;,&quot;title&quot;:&quot;Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696669&quot;,&quot;title&quot;:&quot;Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing&#x27;s Sarcoma in Children and Young Adults&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01716689&quot;,&quot;title&quot;:&quot;Clinical Study of Metronomic Oral Cyclophosphamide in Patients With Advanced Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01719302&quot;,&quot;title&quot;:&quot;Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01822275&quot;,&quot;title&quot;:&quot;Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01848457&quot;,&quot;title&quot;:&quot;Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01864109&quot;,&quot;title&quot;:&quot;Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871766&quot;,&quot;title&quot;:&quot;Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01879085&quot;,&quot;title&quot;:&quot;Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01913652&quot;,&quot;title&quot;:&quot;Ph II Cabazitaxel/Ifosfamide DD Liposarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01946529&quot;,&quot;title&quot;:&quot;Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01977677&quot;,&quot;title&quot;:&quot;Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01987102&quot;,&quot;title&quot;:&quot;Investigation of [6R] 5,10-methylenetetrahydrofolate as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02022358&quot;,&quot;title&quot;:&quot;Will the Use of Glucarpidase After Methotrexate Treatment Allow More Patients With Bone Sarcoma to Have Fewer Side Effects and Receive Subsequent Chemotherapy on Time?&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02029430&quot;,&quot;title&quot;:&quot;A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02050919&quot;,&quot;title&quot;:&quot;Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02052648&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02097238&quot;,&quot;title&quot;:&quot;Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02235701&quot;,&quot;title&quot;:&quot;Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02247544&quot;,&quot;title&quot;:&quot;Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02249702&quot;,&quot;title&quot;:&quot;Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02249949&quot;,&quot;title&quot;:&quot;Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients With Previously Treated, Unresectable Myxoid Liposarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02255110&quot;,&quot;title&quot;:&quot;A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02267083&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02273583&quot;,&quot;title&quot;:&quot;Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02275286&quot;,&quot;title&quot;:&quot;Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00162721&quot;,&quot;title&quot;:&quot;The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00210665&quot;,&quot;title&quot;:&quot;A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00334854&quot;,&quot;title&quot;:&quot;Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00379457&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00392327&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00691236&quot;,&quot;title&quot;:&quot;Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00876031&quot;,&quot;title&quot;:&quot;Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00987636&quot;,&quot;title&quot;:&quot;Study in Localized and Disseminated Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01231906&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01459484&quot;,&quot;title&quot;:&quot;ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01533207&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01692678&quot;,&quot;title&quot;:&quot;A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01987596&quot;,&quot;title&quot;:&quot;Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02049905&quot;,&quot;title&quot;:&quot;Phase 3 Study to Treat Patients With Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02063022&quot;,&quot;title&quot;:&quot;Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02099396&quot;,&quot;title&quot;:&quot;A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">88</td></div></td></tr><tr class=""><td><div><img alt="radiation" height="24" src="../assets/icon-radiation-2142d7789fc4a2dc44afd5eaa933d211.png" width="24" /><span class="intervention">Radiation</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Radiation" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00049023&quot;,&quot;title&quot;:&quot;Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01433068&quot;,&quot;title&quot;:&quot;NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01498835&quot;,&quot;title&quot;:&quot;Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01746238&quot;,&quot;title&quot;:&quot;Bevacizumab/Doxorubicin/Radiation for Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01849146&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01922076&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02287428&quot;,&quot;title&quot;:&quot;Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">7</td><td class="on phases" data-content-name="sarcoma" data-intervention="Radiation" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00356031&quot;,&quot;title&quot;:&quot;Bevacizumab and Radiation Therapy for Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00084695&quot;,&quot;title&quot;:&quot;Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00181025&quot;,&quot;title&quot;:&quot;Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs\u2019 Girdle&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00592293&quot;,&quot;title&quot;:&quot;Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00592592&quot;,&quot;title&quot;:&quot;Proton RT for the Treatment of Pediatric Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00936052&quot;,&quot;title&quot;:&quot;Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01005043&quot;,&quot;title&quot;:&quot;Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01514201&quot;,&quot;title&quot;:&quot;Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01566123&quot;,&quot;title&quot;:&quot;Trial of Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma (RETRO-WTS)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01659203&quot;,&quot;title&quot;:&quot;Proton or Photon RT for Retroperitoneal Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696669&quot;,&quot;title&quot;:&quot;Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing&#x27;s Sarcoma in Children and Young Adults&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01763970&quot;,&quot;title&quot;:&quot;Stereotactic Radiation Therapy for Pediatric Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01819831&quot;,&quot;title&quot;:&quot;A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01822275&quot;,&quot;title&quot;:&quot;Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01833520&quot;,&quot;title&quot;:&quot;Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01841047&quot;,&quot;title&quot;:&quot;Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871766&quot;,&quot;title&quot;:&quot;Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01886105&quot;,&quot;title&quot;:&quot;Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01894061&quot;,&quot;title&quot;:&quot;NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01904565&quot;,&quot;title&quot;:&quot;Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01977677&quot;,&quot;title&quot;:&quot;Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02050919&quot;,&quot;title&quot;:&quot;Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02106312&quot;,&quot;title&quot;:&quot;Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02150213&quot;,&quot;title&quot;:&quot;Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02163135&quot;,&quot;title&quot;:&quot;Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179086&quot;,&quot;title&quot;:&quot;Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02181829&quot;,&quot;title&quot;:&quot;Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02201420&quot;,&quot;title&quot;:&quot;Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek\u00ae) Localization, Retention, and Distribution in Primary Cutaneous Kaposi&#x27;s Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02275286&quot;,&quot;title&quot;:&quot;Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">30</td><td class="on phases" data-content-name="sarcoma" data-intervention="Radiation" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00162721&quot;,&quot;title&quot;:&quot;The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00334854&quot;,&quot;title&quot;:&quot;Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00379457&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00392327&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00870701&quot;,&quot;title&quot;:&quot;Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01087268&quot;,&quot;title&quot;:&quot;Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01223248&quot;,&quot;title&quot;:&quot;Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01344018&quot;,&quot;title&quot;:&quot;Surgery With or Without Radiation Therapy in Treating Patients With Previously Untreated Nonmetastatic Retroperitoneal Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">9</td><td class="on phases" data-content-name="sarcoma" data-intervention="Radiation" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00601406&quot;,&quot;title&quot;:&quot;Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01170299&quot;,&quot;title&quot;:&quot;Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01367301&quot;,&quot;title&quot;:&quot;Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01504360&quot;,&quot;title&quot;:&quot;Predictive Study of Radiation Induced Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01575951&quot;,&quot;title&quot;:&quot;Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01795430&quot;,&quot;title&quot;:&quot;Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01949506&quot;,&quot;title&quot;:&quot;(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01957709&quot;,&quot;title&quot;:&quot;Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01958580&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02062632&quot;,&quot;title&quot;:&quot;Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02162732&quot;,&quot;title&quot;:&quot;Molecular-Guided Therapy for Childhood Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">11</td><td class="on phases" data-content-name="sarcoma" data-intervention="Radiation" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00601406&quot;,&quot;title&quot;:&quot;Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01170299&quot;,&quot;title&quot;:&quot;Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01367301&quot;,&quot;title&quot;:&quot;Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01504360&quot;,&quot;title&quot;:&quot;Predictive Study of Radiation Induced Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01575951&quot;,&quot;title&quot;:&quot;Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01795430&quot;,&quot;title&quot;:&quot;Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01949506&quot;,&quot;title&quot;:&quot;(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01957709&quot;,&quot;title&quot;:&quot;Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01958580&quot;,&quot;title&quot;:&quot;Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02062632&quot;,&quot;title&quot;:&quot;Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02162732&quot;,&quot;title&quot;:&quot;Molecular-Guided Therapy for Childhood Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00049023&quot;,&quot;title&quot;:&quot;Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01433068&quot;,&quot;title&quot;:&quot;NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01498835&quot;,&quot;title&quot;:&quot;Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01746238&quot;,&quot;title&quot;:&quot;Bevacizumab/Doxorubicin/Radiation for Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01849146&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01922076&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02287428&quot;,&quot;title&quot;:&quot;Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00356031&quot;,&quot;title&quot;:&quot;Bevacizumab and Radiation Therapy for Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00084695&quot;,&quot;title&quot;:&quot;Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00181025&quot;,&quot;title&quot;:&quot;Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs\u2019 Girdle&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00592293&quot;,&quot;title&quot;:&quot;Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00592592&quot;,&quot;title&quot;:&quot;Proton RT for the Treatment of Pediatric Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00936052&quot;,&quot;title&quot;:&quot;Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01005043&quot;,&quot;title&quot;:&quot;Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01514201&quot;,&quot;title&quot;:&quot;Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01566123&quot;,&quot;title&quot;:&quot;Trial of Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma (RETRO-WTS)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01659203&quot;,&quot;title&quot;:&quot;Proton or Photon RT for Retroperitoneal Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696669&quot;,&quot;title&quot;:&quot;Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing&#x27;s Sarcoma in Children and Young Adults&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01763970&quot;,&quot;title&quot;:&quot;Stereotactic Radiation Therapy for Pediatric Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01819831&quot;,&quot;title&quot;:&quot;A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01822275&quot;,&quot;title&quot;:&quot;Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01833520&quot;,&quot;title&quot;:&quot;Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01841047&quot;,&quot;title&quot;:&quot;Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871766&quot;,&quot;title&quot;:&quot;Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01886105&quot;,&quot;title&quot;:&quot;Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01894061&quot;,&quot;title&quot;:&quot;NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01904565&quot;,&quot;title&quot;:&quot;Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01977677&quot;,&quot;title&quot;:&quot;Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02050919&quot;,&quot;title&quot;:&quot;Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02106312&quot;,&quot;title&quot;:&quot;Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02150213&quot;,&quot;title&quot;:&quot;Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02163135&quot;,&quot;title&quot;:&quot;Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179086&quot;,&quot;title&quot;:&quot;Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02181829&quot;,&quot;title&quot;:&quot;Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02201420&quot;,&quot;title&quot;:&quot;Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek\u00ae) Localization, Retention, and Distribution in Primary Cutaneous Kaposi&#x27;s Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02275286&quot;,&quot;title&quot;:&quot;Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00162721&quot;,&quot;title&quot;:&quot;The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00334854&quot;,&quot;title&quot;:&quot;Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00379457&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00392327&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00870701&quot;,&quot;title&quot;:&quot;Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01087268&quot;,&quot;title&quot;:&quot;Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01223248&quot;,&quot;title&quot;:&quot;Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01344018&quot;,&quot;title&quot;:&quot;Surgery With or Without Radiation Therapy in Treating Patients With Previously Untreated Nonmetastatic Retroperitoneal Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">57</td></div></td></tr><tr class=""><td><div><img alt="procedure" height="24" src="../assets/icon-procedure-53a976ab34598c312e7a319406d457ee.png" width="24" /><span class="intervention">Surgery</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Surgery" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Surgery" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01552239&quot;,&quot;title&quot;:&quot;Preoperative Radiotherapy for Sarcomas of the Extremities With Intensity-Modulation, Image-Guidance and Small Safety-margins&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696669&quot;,&quot;title&quot;:&quot;Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing&#x27;s Sarcoma in Children and Young Adults&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01819831&quot;,&quot;title&quot;:&quot;A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01841047&quot;,&quot;title&quot;:&quot;Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871766&quot;,&quot;title&quot;:&quot;Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01898962&quot;,&quot;title&quot;:&quot;Definitive Therapy for Oligometastatic Solid Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01986829&quot;,&quot;title&quot;:&quot;Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02005614&quot;,&quot;title&quot;:&quot;A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">8</td><td class="on phases" data-content-name="sarcoma" data-intervention="Surgery" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00334854&quot;,&quot;title&quot;:&quot;Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00379457&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01344018&quot;,&quot;title&quot;:&quot;Surgery With or Without Radiation Therapy in Treating Patients With Previously Untreated Nonmetastatic Retroperitoneal Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">4</td><td class="on phases" data-content-name="sarcoma" data-intervention="Surgery" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00580385&quot;,&quot;title&quot;:&quot;Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01575951&quot;,&quot;title&quot;:&quot;Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02020720&quot;,&quot;title&quot;:&quot;18F-DOPA-PET in Planning Surgery in Patients With Gliomas&quot;,&quot;phase&quot;:&quot;other&quot;}]">3</td><td class="on phases" data-content-name="sarcoma" data-intervention="Surgery" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00580385&quot;,&quot;title&quot;:&quot;Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01575951&quot;,&quot;title&quot;:&quot;Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02020720&quot;,&quot;title&quot;:&quot;18F-DOPA-PET in Planning Surgery in Patients With Gliomas&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01552239&quot;,&quot;title&quot;:&quot;Preoperative Radiotherapy for Sarcomas of the Extremities With Intensity-Modulation, Image-Guidance and Small Safety-margins&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696669&quot;,&quot;title&quot;:&quot;Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing&#x27;s Sarcoma in Children and Young Adults&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01819831&quot;,&quot;title&quot;:&quot;A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01841047&quot;,&quot;title&quot;:&quot;Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871766&quot;,&quot;title&quot;:&quot;Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01898962&quot;,&quot;title&quot;:&quot;Definitive Therapy for Oligometastatic Solid Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01986829&quot;,&quot;title&quot;:&quot;Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02005614&quot;,&quot;title&quot;:&quot;A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00334854&quot;,&quot;title&quot;:&quot;Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00379457&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01344018&quot;,&quot;title&quot;:&quot;Surgery With or Without Radiation Therapy in Treating Patients With Previously Untreated Nonmetastatic Retroperitoneal Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">15</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Other interventions</td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">alpha - TEA</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="alpha - TEA" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02192346&quot;,&quot;title&quot;:&quot;\u03b1-TEA in Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="alpha - TEA" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="alpha - TEA" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="alpha - TEA" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="alpha - TEA" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02192346&quot;,&quot;title&quot;:&quot;\u03b1-TEA in Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Antiretrovirals</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Antiretrovirals" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Antiretrovirals" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Antiretrovirals" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01352117&quot;,&quot;title&quot;:&quot;Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Antiretrovirals" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02080416&quot;,&quot;title&quot;:&quot;Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Antiretrovirals" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02080416&quot;,&quot;title&quot;:&quot;Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01352117&quot;,&quot;title&quot;:&quot;Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="observational" height="24" src="../assets/icon-observational-c850264b8861088b55e7f807fea97d96.png" width="24" /><span class="intervention">Behavioral intervention</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Behavioral intervention" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Behavioral intervention" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Behavioral intervention" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Behavioral intervention" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01764789&quot;,&quot;title&quot;:&quot;Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Behavioral intervention" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01764789&quot;,&quot;title&quot;:&quot;Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Calcitriol</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Calcitriol" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01588522&quot;,&quot;title&quot;:&quot;Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Calcitriol" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Calcitriol" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Calcitriol" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Calcitriol" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01588522&quot;,&quot;title&quot;:&quot;Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="observational" height="24" src="../assets/icon-observational-c850264b8861088b55e7f807fea97d96.png" width="24" /><span class="intervention">Clinical care training</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Clinical care training" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Clinical care training" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Clinical care training" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Clinical care training" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01764360&quot;,&quot;title&quot;:&quot;Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Clinical care training" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01764360&quot;,&quot;title&quot;:&quot;Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="supplement" height="24" src="../assets/icon-supplement-a7b1b1d2ed8cb3e138529cdef4547bc3.png" width="24" /><span class="intervention">Diet</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Diet" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00910884&quot;,&quot;title&quot;:&quot;Natural Supplements and a Special Diet in Eliminating Cancer-impacting Hormones From Sources Outside the Body in Patients With Early-Stage or Remission Prostate Cancer, Breast Cancer, or Uterine Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Diet" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00905658&quot;,&quot;title&quot;:&quot;Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Diet" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00726934&quot;,&quot;title&quot;:&quot;The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Diet" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01170299&quot;,&quot;title&quot;:&quot;Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Diet" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01170299&quot;,&quot;title&quot;:&quot;Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00910884&quot;,&quot;title&quot;:&quot;Natural Supplements and a Special Diet in Eliminating Cancer-impacting Hormones From Sources Outside the Body in Patients With Early-Stage or Remission Prostate Cancer, Breast Cancer, or Uterine Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00905658&quot;,&quot;title&quot;:&quot;Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00726934&quot;,&quot;title&quot;:&quot;The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">4</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Digoxin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Digoxin" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Digoxin" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02212639&quot;,&quot;title&quot;:&quot;Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi&#x27; s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Digoxin" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Digoxin" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Digoxin" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02212639&quot;,&quot;title&quot;:&quot;Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi&#x27; s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="observational" height="24" src="../assets/icon-observational-c850264b8861088b55e7f807fea97d96.png" width="24" /><span class="intervention">Education</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Education" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Education" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Education" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Education" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02096783&quot;,&quot;title&quot;:&quot;Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Education" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02096783&quot;,&quot;title&quot;:&quot;Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Endostatin</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Endostatin" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Endostatin" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01812018&quot;,&quot;title&quot;:&quot;Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Endostatin" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Endostatin" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Endostatin" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01812018&quot;,&quot;title&quot;:&quot;Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">ENMD-2076</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="ENMD-2076" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="ENMD-2076" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01719744&quot;,&quot;title&quot;:&quot;Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="ENMD-2076" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="ENMD-2076" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="ENMD-2076" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01719744&quot;,&quot;title&quot;:&quot;Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="observational" height="24" src="../assets/icon-observational-c850264b8861088b55e7f807fea97d96.png" width="24" /><span class="intervention">Exercise</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Exercise" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Exercise" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Exercise" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Exercise" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01674101&quot;,&quot;title&quot;:&quot;Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Exercise" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01674101&quot;,&quot;title&quot;:&quot;Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">HIV Protease Inhibitor</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="HIV Protease Inhibitor" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="HIV Protease Inhibitor" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01067690&quot;,&quot;title&quot;:&quot;Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="HIV Protease Inhibitor" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="HIV Protease Inhibitor" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="HIV Protease Inhibitor" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01067690&quot;,&quot;title&quot;:&quot;Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="observational" height="24" src="../assets/icon-observational-c850264b8861088b55e7f807fea97d96.png" width="24" /><span class="intervention">Hospice</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Hospice" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Hospice" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Hospice" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Hospice" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02069769&quot;,&quot;title&quot;:&quot;Ensuring Communication in Hospice by Oncology Study (ECHO)&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Hospice" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02069769&quot;,&quot;title&quot;:&quot;Ensuring Communication in Hospice by Oncology Study (ECHO)&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Hyperthermia treatment</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Hyperthermia treatment" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Hyperthermia treatment" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Hyperthermia treatment" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Hyperthermia treatment" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01896778&quot;,&quot;title&quot;:&quot;Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Hyperthermia treatment" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01896778&quot;,&quot;title&quot;:&quot;Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">NGR-hTNF</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="NGR-hTNF" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="NGR-hTNF" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00484341&quot;,&quot;title&quot;:&quot;Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="NGR-hTNF" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="NGR-hTNF" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="NGR-hTNF" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00484341&quot;,&quot;title&quot;:&quot;Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="supplement" height="24" src="../assets/icon-supplement-a7b1b1d2ed8cb3e138529cdef4547bc3.png" width="24" /><span class="intervention">Plants + herb mix</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Plants + herb mix" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Plants + herb mix" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00689195&quot;,&quot;title&quot;:&quot;Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Plants + herb mix" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Plants + herb mix" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Plants + herb mix" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00689195&quot;,&quot;title&quot;:&quot;Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Prostate Specific Membrane Antigen (PSMA)</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Prostate Specific Membrane Antigen (PSMA)" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Prostate Specific Membrane Antigen (PSMA)" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01856933&quot;,&quot;title&quot;:&quot;BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Prostate Specific Membrane Antigen (PSMA)" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Prostate Specific Membrane Antigen (PSMA)" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Prostate Specific Membrane Antigen (PSMA)" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01856933&quot;,&quot;title&quot;:&quot;BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Selinexor</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Selinexor" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01896505&quot;,&quot;title&quot;:&quot;A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Selinexor" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Selinexor" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Selinexor" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Selinexor" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01896505&quot;,&quot;title&quot;:&quot;A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="procedure" height="24" src="../assets/icon-procedure-53a976ab34598c312e7a319406d457ee.png" width="24" /><span class="intervention">Stem cell transplant</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Stem cell transplant" data-phase="phase1" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01969942&quot;,&quot;title&quot;:&quot;A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory EWING SARCOMA and RHABDOMYOSARCOMA&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02015819&quot;,&quot;title&quot;:&quot;Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin Calcium in Treating Patients With Recurrent High-Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02192359&quot;,&quot;title&quot;:&quot;Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">4</td><td class="on phases" data-content-name="sarcoma" data-intervention="Stem cell transplant" data-phase="phase2" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01807468&quot;,&quot;title&quot;:&quot;Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02259348&quot;,&quot;title&quot;:&quot;Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00084695&quot;,&quot;title&quot;:&quot;Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00179816&quot;,&quot;title&quot;:&quot;Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00978471&quot;,&quot;title&quot;:&quot;Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">5</td><td class="on phases" data-content-name="sarcoma" data-intervention="Stem cell transplant" data-phase="phase3" data-placement="bottom" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Stem cell transplant" data-phase="other" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01272817&quot;,&quot;title&quot;:&quot;Nonmyeloablative Allogeneic Transplant&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01795430&quot;,&quot;title&quot;:&quot;Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;}]">2</td><td class="on phases" data-content-name="sarcoma" data-intervention="Stem cell transplant" data-phase="all" data-placement="bottom_left" data-popup-id="adult-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01272817&quot;,&quot;title&quot;:&quot;Nonmyeloablative Allogeneic Transplant&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01795430&quot;,&quot;title&quot;:&quot;Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01969942&quot;,&quot;title&quot;:&quot;A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory EWING SARCOMA and RHABDOMYOSARCOMA&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02015819&quot;,&quot;title&quot;:&quot;Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin Calcium in Treating Patients With Recurrent High-Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02192359&quot;,&quot;title&quot;:&quot;Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01807468&quot;,&quot;title&quot;:&quot;Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02259348&quot;,&quot;title&quot;:&quot;Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00084695&quot;,&quot;title&quot;:&quot;Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00179816&quot;,&quot;title&quot;:&quot;Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00978471&quot;,&quot;title&quot;:&quot;Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">12</td></div></td></tr>
</table>
<p>
*
<em>Phase 4 or compassionate care study</em>
<br>
**
<em>Only ongoing studies are included (recruiting, pending recruitment or active, but not yet recruiting)</em>
</p>
<p>
<a href="../contact-subject=The+Adult+Sarcoma+trial+table+is+missing+a+trial&trial_table=Adult+Sarcoma.html" rel="nofollow">Are we missing a trial?</a>
</p>
<div class='popover-div' id='adult-sarcoma'></div>
</div><div class="trial_table pediatric-sarcoma_table hide"><table class='pediatric-sarcoma' data-condition-name='Pediatric Sarcoma' id='trial-widget'>
<tr>
<th>
<div class='condition_name'>
Pediatric Sarcoma
</div>
</th>
<th>
<div class='big'>
25
</div>
<div class='th_label'>
phase 1
</div>
</th>
<th>
<div class='big'>
73
</div>
<div class='th_label'>
phase 2
</div>
</th>
<th>
<div class='big'>
26
</div>
<div class='th_label'>
phase 3
</div>
</th>
<th>
<div class='big'>
12
</div>
<div class='th_label'>
other*
</div>
</th>
<th>
<div class='big'>
136
</div>
<div class='th_label'>total</div>
</th>
</tr>
<tr class="subheader_0"><td colspan="6">Targeted Therapy</td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="ALK" data-id="pediatric-sarcoma" data-name="alk_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">ALK</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="ALK" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="ALK" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01524926&quot;,&quot;title&quot;:&quot;CREATE: Cross-tumoral Phase 2 With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="ALK" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="ALK" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="ALK" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01524926&quot;,&quot;title&quot;:&quot;CREATE: Cross-tumoral Phase 2 With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class="alk_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Crizotinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Crizotinib" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Crizotinib" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01524926&quot;,&quot;title&quot;:&quot;CREATE: Cross-tumoral Phase 2 With Crizotinib&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Crizotinib" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Crizotinib" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Crizotinib" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="CDK 4/6" data-id="pediatric-sarcoma" data-name="cdk-4-6_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">CDK 4/6</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="CDK 4/6" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02255461&quot;,&quot;title&quot;:&quot;Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="CDK 4/6" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="CDK 4/6" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="CDK 4/6" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="CDK 4/6" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02255461&quot;,&quot;title&quot;:&quot;Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class="cdk-4-6_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Palbociclib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Palbociclib" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02255461&quot;,&quot;title&quot;:&quot;Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Palbociclib" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Palbociclib" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Palbociclib" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Palbociclib" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Histone deacetylase (HDAC/HDI)" data-id="pediatric-sarcoma" data-name="histone-deacetylase-hdac-hdi_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Histone deacetylase (HDAC/HDI)</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Histone deacetylase (HDAC/HDI)" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class="histone-deacetylase-hdac-hdi_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Valproic acid</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Valproic acid" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Valproic acid" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Valproic acid" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Valproic acid" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Valproic acid" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="mTOR" data-id="pediatric-sarcoma" data-name="mtor_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">mTOR</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="mTOR" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="mTOR" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01216826&quot;,&quot;title&quot;:&quot;Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="mTOR" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="mTOR" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="mTOR" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01216826&quot;,&quot;title&quot;:&quot;Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr><tr class="mtor_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Everolimus</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Everolimus" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Everolimus" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01216826&quot;,&quot;title&quot;:&quot;Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Everolimus" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Everolimus" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Everolimus" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="mtor_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sirolimus</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Sirolimus" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Sirolimus" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sirolimus" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sirolimus" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sirolimus" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Multikinase inhibitors" data-id="pediatric-sarcoma" data-name="multikinase-inhibitors_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Multikinase inhibitors</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Multikinase inhibitors" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01518413&quot;,&quot;title&quot;:&quot;Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Multikinase inhibitors" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01140737&quot;,&quot;title&quot;:&quot;A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02243605&quot;,&quot;title&quot;:&quot;Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01759303&quot;,&quot;title&quot;:&quot;Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00753727&quot;,&quot;title&quot;:&quot;Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391962&quot;,&quot;title&quot;:&quot;Sunitinib or Cediranib for Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">5</td><td class="on phases" data-content-name="sarcoma" data-intervention="Multikinase inhibitors" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02180867&quot;,&quot;title&quot;:&quot;Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Multikinase inhibitors" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Multikinase inhibitors" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01518413&quot;,&quot;title&quot;:&quot;Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01140737&quot;,&quot;title&quot;:&quot;A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02243605&quot;,&quot;title&quot;:&quot;Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01759303&quot;,&quot;title&quot;:&quot;Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00753727&quot;,&quot;title&quot;:&quot;Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391962&quot;,&quot;title&quot;:&quot;Sunitinib or Cediranib for Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02180867&quot;,&quot;title&quot;:&quot;Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">7</td></div></td></tr><tr class="multikinase-inhibitors_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Axitinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Axitinib" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Axitinib" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01140737&quot;,&quot;title&quot;:&quot;A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Axitinib" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Axitinib" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Axitinib" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="multikinase-inhibitors_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cabozantinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Cabozantinib" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Cabozantinib" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02243605&quot;,&quot;title&quot;:&quot;Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Cabozantinib" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Cabozantinib" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Cabozantinib" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="multikinase-inhibitors_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Pazopanib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Pazopanib" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Pazopanib" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01759303&quot;,&quot;title&quot;:&quot;Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Pazopanib" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02180867&quot;,&quot;title&quot;:&quot;Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Pazopanib" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Pazopanib" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">2</td></div></td></tr><tr class="multikinase-inhibitors_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sorafinib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Sorafinib" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01518413&quot;,&quot;title&quot;:&quot;Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Sorafinib" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sorafinib" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sorafinib" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sorafinib" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="multikinase-inhibitors_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sunitinib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Sunitinib" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Sunitinib" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00753727&quot;,&quot;title&quot;:&quot;Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391962&quot;,&quot;title&quot;:&quot;Sunitinib or Cediranib for Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="sarcoma" data-intervention="Sunitinib" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sunitinib" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Sunitinib" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">2</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="Other antibodies or immunologics" data-id="pediatric-sarcoma" data-name="other-antibodies-or-immunologics_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Other antibodies or immunologics</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Other antibodies or immunologics" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02107963&quot;,&quot;title&quot;:&quot;A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With Non-neuroblastoma, GD2+ Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00743496&quot;,&quot;title&quot;:&quot;A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01875601&quot;,&quot;title&quot;:&quot;NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00062868&quot;,&quot;title&quot;:&quot;LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01922076&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">6</td><td class="on phases" data-content-name="sarcoma" data-intervention="Other antibodies or immunologics" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02173093&quot;,&quot;title&quot;:&quot;Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02052648&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01590069&quot;,&quot;title&quot;:&quot;Aerosol IL-2 for Pulmonary Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02095132&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01288573&quot;,&quot;title&quot;:&quot;A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">5</td><td data-content-name="sarcoma" data-intervention="Other antibodies or immunologics" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Other antibodies or immunologics" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Other antibodies or immunologics" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02107963&quot;,&quot;title&quot;:&quot;A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With Non-neuroblastoma, GD2+ Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00743496&quot;,&quot;title&quot;:&quot;A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01875601&quot;,&quot;title&quot;:&quot;NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00062868&quot;,&quot;title&quot;:&quot;LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01922076&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02173093&quot;,&quot;title&quot;:&quot;Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02052648&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01590069&quot;,&quot;title&quot;:&quot;Aerosol IL-2 for Pulmonary Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02095132&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01288573&quot;,&quot;title&quot;:&quot;A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">11</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Activated T Cells</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Activated T Cells" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02107963&quot;,&quot;title&quot;:&quot;A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With Non-neuroblastoma, GD2+ Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Activated T Cells" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02173093&quot;,&quot;title&quot;:&quot;Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Activated T Cells" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Activated T Cells" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Activated T Cells" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">2</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Alemtuzumab</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Alemtuzumab" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Alemtuzumab" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Alemtuzumab" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Alemtuzumab" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Alemtuzumab" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Humanized Anti-GD2 Antibody</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Humanized Anti-GD2 Antibody" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00743496&quot;,&quot;title&quot;:&quot;A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Humanized Anti-GD2 Antibody" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Humanized Anti-GD2 Antibody" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Humanized Anti-GD2 Antibody" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Humanized Anti-GD2 Antibody" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">IDO Inhibitor</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="IDO Inhibitor" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="IDO Inhibitor" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02052648&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="IDO Inhibitor" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="IDO Inhibitor" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="IDO Inhibitor" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Interleukin-2</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Interleukin-2" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01875601&quot;,&quot;title&quot;:&quot;NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Interleukin-2" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01590069&quot;,&quot;title&quot;:&quot;Aerosol IL-2 for Pulmonary Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Interleukin-2" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Interleukin-2" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Interleukin-2" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">2</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">LMP- specific cytotoxic T lymphocytes</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="LMP- specific cytotoxic T lymphocytes" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00062868&quot;,&quot;title&quot;:&quot;LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="LMP- specific cytotoxic T lymphocytes" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="LMP- specific cytotoxic T lymphocytes" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="LMP- specific cytotoxic T lymphocytes" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="LMP- specific cytotoxic T lymphocytes" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MK-1775</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="MK-1775" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01922076&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="MK-1775" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02095132&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="MK-1775" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="MK-1775" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="MK-1775" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">2</td></div></td></tr><tr class="other-antibodies-or-immunologics_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Plerixafor</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Plerixafor" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Plerixafor" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01288573&quot;,&quot;title&quot;:&quot;A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Plerixafor" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Plerixafor" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Plerixafor" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="PARP" data-id="pediatric-sarcoma" data-name="parp_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">PARP</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="PARP" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02044120&quot;,&quot;title&quot;:&quot;ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="PARP" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02116777&quot;,&quot;title&quot;:&quot;BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01514201&quot;,&quot;title&quot;:&quot;Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="sarcoma" data-intervention="PARP" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="PARP" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="PARP" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02044120&quot;,&quot;title&quot;:&quot;ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02116777&quot;,&quot;title&quot;:&quot;BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01514201&quot;,&quot;title&quot;:&quot;Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td></div></td></tr><tr class="parp_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">BMN-673</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="BMN-673" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="BMN-673" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02116777&quot;,&quot;title&quot;:&quot;BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="BMN-673" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="BMN-673" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="BMN-673" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="parp_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Niraparib</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Niraparib" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02044120&quot;,&quot;title&quot;:&quot;ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Niraparib" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Niraparib" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Niraparib" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Niraparib" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="parp_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Veliparib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Veliparib" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Veliparib" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01514201&quot;,&quot;title&quot;:&quot;Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Veliparib" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Veliparib" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Veliparib" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">1</td></div></td></tr><tr class="category "><td><div><span class="zippy pull-right" data-friendly-name="VEGF" data-id="pediatric-sarcoma" data-name="vegf_targeted-therapy"></span><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">VEGF</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="VEGF" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="VEGF" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217437&quot;,&quot;title&quot;:&quot;Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01492673&quot;,&quot;title&quot;:&quot;Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing&#x27;s Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00942877&quot;,&quot;title&quot;:&quot;Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01337401&quot;,&quot;title&quot;:&quot;A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391962&quot;,&quot;title&quot;:&quot;Sunitinib or Cediranib for Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">6</td><td data-content-name="sarcoma" data-intervention="VEGF" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="VEGF" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01189643&quot;,&quot;title&quot;:&quot;Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="VEGF" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01189643&quot;,&quot;title&quot;:&quot;Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217437&quot;,&quot;title&quot;:&quot;Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01492673&quot;,&quot;title&quot;:&quot;Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing&#x27;s Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00942877&quot;,&quot;title&quot;:&quot;Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01337401&quot;,&quot;title&quot;:&quot;A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391962&quot;,&quot;title&quot;:&quot;Sunitinib or Cediranib for Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">7</td></div></td></tr><tr class="vegf_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Bevacizumab</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Bevacizumab" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Bevacizumab" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217437&quot;,&quot;title&quot;:&quot;Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01492673&quot;,&quot;title&quot;:&quot;Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing&#x27;s Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="sarcoma" data-intervention="Bevacizumab" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Bevacizumab" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01189643&quot;,&quot;title&quot;:&quot;Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Bevacizumab" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">4</td></div></td></tr><tr class="vegf_targeted-therapy hide"><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cediranib</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Cediranib" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Cediranib" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00942877&quot;,&quot;title&quot;:&quot;Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01337401&quot;,&quot;title&quot;:&quot;A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01391962&quot;,&quot;title&quot;:&quot;Sunitinib or Cediranib for Alveolar Soft Part Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td data-content-name="sarcoma" data-intervention="Cediranib" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Cediranib" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Cediranib" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="null">3</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Vaccines</td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Autologous Activated Natural Killer (NK) Cells</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous Activated Natural Killer (NK) Cells" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01875601&quot;,&quot;title&quot;:&quot;NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Autologous Activated Natural Killer (NK) Cells" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Autologous Activated Natural Killer (NK) Cells" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Autologous Activated Natural Killer (NK) Cells" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous Activated Natural Killer (NK) Cells" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01875601&quot;,&quot;title&quot;:&quot;NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Autologous Tumor Cell Vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous Tumor Cell Vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01061840&quot;,&quot;title&quot;:&quot;Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Autologous Tumor Cell Vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Autologous Tumor Cell Vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Autologous Tumor Cell Vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Autologous Tumor Cell Vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01061840&quot;,&quot;title&quot;:&quot;Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Dendritic Cell Vaccine</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Dendritic Cell Vaccine" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01241162&quot;,&quot;title&quot;:&quot;Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01803152&quot;,&quot;title&quot;:&quot;Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td data-content-name="sarcoma" data-intervention="Dendritic Cell Vaccine" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Dendritic Cell Vaccine" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Dendritic Cell Vaccine" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Dendritic Cell Vaccine" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01241162&quot;,&quot;title&quot;:&quot;Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01803152&quot;,&quot;title&quot;:&quot;Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">New castle disease virus</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="New castle disease virus" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="New castle disease virus" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01174537&quot;,&quot;title&quot;:&quot;New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="New castle disease virus" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="New castle disease virus" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="New castle disease virus" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01174537&quot;,&quot;title&quot;:&quot;New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Oncolytic HSV-1716</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Oncolytic HSV-1716" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02031965&quot;,&quot;title&quot;:&quot;Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Oncolytic HSV-1716" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Oncolytic HSV-1716" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Oncolytic HSV-1716" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Oncolytic HSV-1716" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02031965&quot;,&quot;title&quot;:&quot;Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Tumor Adoptive T Cell Therapy</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Tumor Adoptive T Cell Therapy" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01343043&quot;,&quot;title&quot;:&quot;A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Tumor Adoptive T Cell Therapy" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01326104&quot;,&quot;title&quot;:&quot;Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Tumor Adoptive T Cell Therapy" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Tumor Adoptive T Cell Therapy" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Tumor Adoptive T Cell Therapy" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01343043&quot;,&quot;title&quot;:&quot;A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01326104&quot;,&quot;title&quot;:&quot;Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Chemotherapy, Radiation, &amp; Surgery</td></tr><tr class=""><td><div><img alt="procedure" height="24" src="../assets/icon-procedure-53a976ab34598c312e7a319406d457ee.png" width="24" /><span class="intervention">Chemotherapy</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Chemotherapy" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01803152&quot;,&quot;title&quot;:&quot;Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01241162&quot;,&quot;title&quot;:&quot;Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02013336&quot;,&quot;title&quot;:&quot;Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02094625&quot;,&quot;title&quot;:&quot;NAC to Prevent Cisplatin-induced Hearing Loss&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02164097&quot;,&quot;title&quot;:&quot;ODSH + ICE Chemotherapy in Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">5</td><td class="on phases" data-content-name="sarcoma" data-intervention="Chemotherapy" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00179816&quot;,&quot;title&quot;:&quot;Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00180791&quot;,&quot;title&quot;:&quot;High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00180947&quot;,&quot;title&quot;:&quot;Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00245089&quot;,&quot;title&quot;:&quot;Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00245141&quot;,&quot;title&quot;:&quot;Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00936156&quot;,&quot;title&quot;:&quot;Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00978471&quot;,&quot;title&quot;:&quot;Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217437&quot;,&quot;title&quot;:&quot;Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01380275&quot;,&quot;title&quot;:&quot;Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01492673&quot;,&quot;title&quot;:&quot;Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing&#x27;s Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01610570&quot;,&quot;title&quot;:&quot;Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01650090&quot;,&quot;title&quot;:&quot;Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696669&quot;,&quot;title&quot;:&quot;Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing&#x27;s Sarcoma in Children and Young Adults&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01848457&quot;,&quot;title&quot;:&quot;Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01864109&quot;,&quot;title&quot;:&quot;Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871766&quot;,&quot;title&quot;:&quot;Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01946529&quot;,&quot;title&quot;:&quot;Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01962103&quot;,&quot;title&quot;:&quot;To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01987102&quot;,&quot;title&quot;:&quot;Investigation of [6R] 5,10-methylenetetrahydrofolate as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02022358&quot;,&quot;title&quot;:&quot;Will the Use of Glucarpidase After Methotrexate Treatment Allow More Patients With Bone Sarcoma to Have Fewer Side Effects and Receive Subsequent Chemotherapy on Time?&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02052648&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02097238&quot;,&quot;title&quot;:&quot;Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02235701&quot;,&quot;title&quot;:&quot;Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02255110&quot;,&quot;title&quot;:&quot;A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02273583&quot;,&quot;title&quot;:&quot;Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">25</td><td class="on phases" data-content-name="sarcoma" data-intervention="Chemotherapy" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00210665&quot;,&quot;title&quot;:&quot;A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00334854&quot;,&quot;title&quot;:&quot;Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00379457&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00392327&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00876031&quot;,&quot;title&quot;:&quot;Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00987636&quot;,&quot;title&quot;:&quot;Study in Localized and Disseminated Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01176981&quot;,&quot;title&quot;:&quot;Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01231906&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01459484&quot;,&quot;title&quot;:&quot;ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01692678&quot;,&quot;title&quot;:&quot;A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01987596&quot;,&quot;title&quot;:&quot;Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02049905&quot;,&quot;title&quot;:&quot;Phase 3 Study to Treat Patients With Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02063022&quot;,&quot;title&quot;:&quot;Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02099396&quot;,&quot;title&quot;:&quot;A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">15</td><td class="on phases" data-content-name="sarcoma" data-intervention="Chemotherapy" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00001686&quot;,&quot;title&quot;:&quot;Evaluation, Treatment, and Natural History of Children With Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01189643&quot;,&quot;title&quot;:&quot;Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01661400&quot;,&quot;title&quot;:&quot;Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01669369&quot;,&quot;title&quot;:&quot;Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01795430&quot;,&quot;title&quot;:&quot;Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;}]">5</td><td class="on phases" data-content-name="sarcoma" data-intervention="Chemotherapy" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00001686&quot;,&quot;title&quot;:&quot;Evaluation, Treatment, and Natural History of Children With Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01189643&quot;,&quot;title&quot;:&quot;Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01661400&quot;,&quot;title&quot;:&quot;Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01669369&quot;,&quot;title&quot;:&quot;Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01795430&quot;,&quot;title&quot;:&quot;Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01803152&quot;,&quot;title&quot;:&quot;Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01241162&quot;,&quot;title&quot;:&quot;Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02013336&quot;,&quot;title&quot;:&quot;Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02094625&quot;,&quot;title&quot;:&quot;NAC to Prevent Cisplatin-induced Hearing Loss&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02164097&quot;,&quot;title&quot;:&quot;ODSH + ICE Chemotherapy in Pediatric Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00179816&quot;,&quot;title&quot;:&quot;Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00180791&quot;,&quot;title&quot;:&quot;High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00180947&quot;,&quot;title&quot;:&quot;Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00245089&quot;,&quot;title&quot;:&quot;Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00245141&quot;,&quot;title&quot;:&quot;Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00936156&quot;,&quot;title&quot;:&quot;Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00978471&quot;,&quot;title&quot;:&quot;Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01217437&quot;,&quot;title&quot;:&quot;Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01380275&quot;,&quot;title&quot;:&quot;Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01492673&quot;,&quot;title&quot;:&quot;Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing&#x27;s Sarcoma and Neuroblastoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01610570&quot;,&quot;title&quot;:&quot;Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01650090&quot;,&quot;title&quot;:&quot;Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696669&quot;,&quot;title&quot;:&quot;Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing&#x27;s Sarcoma in Children and Young Adults&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01848457&quot;,&quot;title&quot;:&quot;Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01864109&quot;,&quot;title&quot;:&quot;Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871766&quot;,&quot;title&quot;:&quot;Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01946529&quot;,&quot;title&quot;:&quot;Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01962103&quot;,&quot;title&quot;:&quot;To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01987102&quot;,&quot;title&quot;:&quot;Investigation of [6R] 5,10-methylenetetrahydrofolate as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02022358&quot;,&quot;title&quot;:&quot;Will the Use of Glucarpidase After Methotrexate Treatment Allow More Patients With Bone Sarcoma to Have Fewer Side Effects and Receive Subsequent Chemotherapy on Time?&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02052648&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02097238&quot;,&quot;title&quot;:&quot;Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02235701&quot;,&quot;title&quot;:&quot;Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02255110&quot;,&quot;title&quot;:&quot;A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02273583&quot;,&quot;title&quot;:&quot;Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00210665&quot;,&quot;title&quot;:&quot;A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00334854&quot;,&quot;title&quot;:&quot;Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00379457&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00392327&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00876031&quot;,&quot;title&quot;:&quot;Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00987636&quot;,&quot;title&quot;:&quot;Study in Localized and Disseminated Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01176981&quot;,&quot;title&quot;:&quot;Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01231906&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01459484&quot;,&quot;title&quot;:&quot;ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01692678&quot;,&quot;title&quot;:&quot;A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01987596&quot;,&quot;title&quot;:&quot;Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02049905&quot;,&quot;title&quot;:&quot;Phase 3 Study to Treat Patients With Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02063022&quot;,&quot;title&quot;:&quot;Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02099396&quot;,&quot;title&quot;:&quot;A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">50</td></div></td></tr><tr class=""><td><div><img alt="radiation" height="24" src="../assets/icon-radiation-2142d7789fc4a2dc44afd5eaa933d211.png" width="24" /><span class="intervention">Radiation</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Radiation" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00049023&quot;,&quot;title&quot;:&quot;Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01922076&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="sarcoma" data-intervention="Radiation" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00036712&quot;,&quot;title&quot;:&quot;Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00084695&quot;,&quot;title&quot;:&quot;Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00180791&quot;,&quot;title&quot;:&quot;High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00181025&quot;,&quot;title&quot;:&quot;Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs\u2019 Girdle&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00592293&quot;,&quot;title&quot;:&quot;Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00592592&quot;,&quot;title&quot;:&quot;Proton RT for the Treatment of Pediatric Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01005043&quot;,&quot;title&quot;:&quot;Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01514201&quot;,&quot;title&quot;:&quot;Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696669&quot;,&quot;title&quot;:&quot;Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing&#x27;s Sarcoma in Children and Young Adults&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01763970&quot;,&quot;title&quot;:&quot;Stereotactic Radiation Therapy for Pediatric Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01833520&quot;,&quot;title&quot;:&quot;Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871766&quot;,&quot;title&quot;:&quot;Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01886105&quot;,&quot;title&quot;:&quot;Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02181829&quot;,&quot;title&quot;:&quot;Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">15</td><td class="on phases" data-content-name="sarcoma" data-intervention="Radiation" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00334854&quot;,&quot;title&quot;:&quot;Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00379457&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00392327&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01734863&quot;,&quot;title&quot;:&quot;Post-operative Radiotherapy in Poor Responders Ewing&#x27;s Sarcoma Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">5</td><td class="on phases" data-content-name="sarcoma" data-intervention="Radiation" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01795430&quot;,&quot;title&quot;:&quot;Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02162732&quot;,&quot;title&quot;:&quot;Molecular-Guided Therapy for Childhood Cancer&quot;,&quot;phase&quot;:&quot;other&quot;}]">2</td><td class="on phases" data-content-name="sarcoma" data-intervention="Radiation" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01795430&quot;,&quot;title&quot;:&quot;Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02162732&quot;,&quot;title&quot;:&quot;Molecular-Guided Therapy for Childhood Cancer&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00049023&quot;,&quot;title&quot;:&quot;Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01922076&quot;,&quot;title&quot;:&quot;WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00036712&quot;,&quot;title&quot;:&quot;Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00084695&quot;,&quot;title&quot;:&quot;Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00180791&quot;,&quot;title&quot;:&quot;High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00181025&quot;,&quot;title&quot;:&quot;Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs\u2019 Girdle&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00592293&quot;,&quot;title&quot;:&quot;Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00592592&quot;,&quot;title&quot;:&quot;Proton RT for the Treatment of Pediatric Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00879437&quot;,&quot;title&quot;:&quot;Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01005043&quot;,&quot;title&quot;:&quot;Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01514201&quot;,&quot;title&quot;:&quot;Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696669&quot;,&quot;title&quot;:&quot;Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing&#x27;s Sarcoma in Children and Young Adults&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01763970&quot;,&quot;title&quot;:&quot;Stereotactic Radiation Therapy for Pediatric Sarcomas&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01833520&quot;,&quot;title&quot;:&quot;Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871766&quot;,&quot;title&quot;:&quot;Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01886105&quot;,&quot;title&quot;:&quot;Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02181829&quot;,&quot;title&quot;:&quot;Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00334854&quot;,&quot;title&quot;:&quot;Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00379457&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00392327&quot;,&quot;title&quot;:&quot;Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01734863&quot;,&quot;title&quot;:&quot;Post-operative Radiotherapy in Poor Responders Ewing&#x27;s Sarcoma Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">24</td></div></td></tr><tr class=""><td><div><img alt="procedure" height="24" src="../assets/icon-procedure-53a976ab34598c312e7a319406d457ee.png" width="24" /><span class="intervention">Surgery</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Surgery" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Surgery" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00180791&quot;,&quot;title&quot;:&quot;High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696669&quot;,&quot;title&quot;:&quot;Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing&#x27;s Sarcoma in Children and Young Adults&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871766&quot;,&quot;title&quot;:&quot;Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td class="on phases" data-content-name="sarcoma" data-intervention="Surgery" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00334854&quot;,&quot;title&quot;:&quot;Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00379457&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">3</td><td class="on phases" data-content-name="sarcoma" data-intervention="Surgery" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02020720&quot;,&quot;title&quot;:&quot;18F-DOPA-PET in Planning Surgery in Patients With Gliomas&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Surgery" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02020720&quot;,&quot;title&quot;:&quot;18F-DOPA-PET in Planning Surgery in Patients With Gliomas&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00180791&quot;,&quot;title&quot;:&quot;High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696669&quot;,&quot;title&quot;:&quot;Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing&#x27;s Sarcoma in Children and Young Adults&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01871766&quot;,&quot;title&quot;:&quot;Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00334854&quot;,&quot;title&quot;:&quot;Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00379457&quot;,&quot;title&quot;:&quot;Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">7</td></div></td></tr>
<tr class="subheader_0"><td colspan="6">Other interventions</td></tr><tr class=""><td><div><img alt="observational" height="24" src="../assets/icon-observational-c850264b8861088b55e7f807fea97d96.png" width="24" /><span class="intervention">Clinical care training</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Clinical care training" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Clinical care training" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Clinical care training" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Clinical care training" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01764360&quot;,&quot;title&quot;:&quot;Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Clinical care training" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01764360&quot;,&quot;title&quot;:&quot;Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="supplement" height="24" src="../assets/icon-supplement-a7b1b1d2ed8cb3e138529cdef4547bc3.png" width="24" /><span class="intervention">Diet</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Diet" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Diet" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Diet" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00726934&quot;,&quot;title&quot;:&quot;The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Diet" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Diet" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00726934&quot;,&quot;title&quot;:&quot;The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="observational" height="24" src="../assets/icon-observational-c850264b8861088b55e7f807fea97d96.png" width="24" /><span class="intervention">Exercise</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Exercise" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Exercise" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Exercise" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Exercise" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01674101&quot;,&quot;title&quot;:&quot;Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Exercise" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01674101&quot;,&quot;title&quot;:&quot;Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="supplement" height="24" src="../assets/icon-supplement-a7b1b1d2ed8cb3e138529cdef4547bc3.png" width="24" /><span class="intervention">Plants + herb mix</span><em class="manufacturer"></em><div class="clearfix"></div><td data-content-name="sarcoma" data-intervention="Plants + herb mix" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Plants + herb mix" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00689195&quot;,&quot;title&quot;:&quot;Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="sarcoma" data-intervention="Plants + herb mix" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td data-content-name="sarcoma" data-intervention="Plants + herb mix" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="sarcoma" data-intervention="Plants + herb mix" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00689195&quot;,&quot;title&quot;:&quot;Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></div></td></tr><tr class=""><td><div><img alt="procedure" height="24" src="../assets/icon-procedure-53a976ab34598c312e7a319406d457ee.png" width="24" /><span class="intervention">Stem cell transplant</span><em class="manufacturer"></em><div class="clearfix"></div><td class="on phases" data-content-name="sarcoma" data-intervention="Stem cell transplant" data-phase="phase1" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01969942&quot;,&quot;title&quot;:&quot;A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory EWING SARCOMA and RHABDOMYOSARCOMA&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="sarcoma" data-intervention="Stem cell transplant" data-phase="phase2" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01807468&quot;,&quot;title&quot;:&quot;Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02259348&quot;,&quot;title&quot;:&quot;Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00084695&quot;,&quot;title&quot;:&quot;Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00179816&quot;,&quot;title&quot;:&quot;Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00180791&quot;,&quot;title&quot;:&quot;High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00978471&quot;,&quot;title&quot;:&quot;Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">6</td><td class="on phases" data-content-name="sarcoma" data-intervention="Stem cell transplant" data-phase="phase3" data-placement="bottom" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Stem cell transplant" data-phase="other" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01795430&quot;,&quot;title&quot;:&quot;Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="sarcoma" data-intervention="Stem cell transplant" data-phase="all" data-placement="bottom_left" data-popup-id="pediatric-sarcoma" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01795430&quot;,&quot;title&quot;:&quot;Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01625351&quot;,&quot;title&quot;:&quot;A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01969942&quot;,&quot;title&quot;:&quot;A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory EWING SARCOMA and RHABDOMYOSARCOMA&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01807468&quot;,&quot;title&quot;:&quot;Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02259348&quot;,&quot;title&quot;:&quot;Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00084695&quot;,&quot;title&quot;:&quot;Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00179816&quot;,&quot;title&quot;:&quot;Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00180791&quot;,&quot;title&quot;:&quot;High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00978471&quot;,&quot;title&quot;:&quot;Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00020566&quot;,&quot;title&quot;:&quot;Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing&#x27;s Sarcoma&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">10</td></div></td></tr>
</table>
<p>
*
<em>Phase 4 or compassionate care study</em>
<br>
**
<em>Only ongoing studies are included (recruiting, pending recruitment or active, but not yet recruiting)</em>
</p>
<p>
<a href="../contact-subject=The+Pediatric+Sarcoma+trial+table+is+missing+a+trial&trial_table=Pediatric+Sarcoma.html" rel="nofollow">Are we missing a trial?</a>
</p>
<div class='popover-div' id='pediatric-sarcoma'></div>
</div></div>
</div>
</div>

</div>
<div class='span3 sidebar no-padding-or-margin'>

<div class='widget '>
<div class='community-promo'>
<h1><a href="../communities/sarcoma.html">Sarcoma at Smart Patients</a></h1>
<p>
The Smart Patients sarcoma community, where patients and caregivers affected by sarcoma learn from each other.
</p>
</div>

<hr>
</div>
<div class='widget '>
<div class='invitation-widget'>
<h2>Join the conversation!</h2>
<form accept-charset="UTF-8" action="/users" class="signup form-inline" id="new_user" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="anHdzK0RV47A1fm+Cc5YWchDmz7Dd1CW3v8C5VSfjds=" /></div><div class='join-button'>
<input class="btn btn-primary join-btn" name="commit" type="submit" value="Join Now" />
</div>
<div class="control-group required"><div class="controls"><input class="email required ezpz" id="invitation_email" name="user[email]" placeholder="Enter your email address" required="required" size="30" type="text" /></div></div>
<div class="notice"><p>If you're not a patient or caregiver, <a href="../contact-subject=Joining+Smart+Patients.html">click here</a>.</p></div>
<div class='notice'>
<p class='already-a-member'>Already a member? <a href="../signin.html">Sign in</a>.</p>
</div>
<input id="community" name="community" type="hidden" value="sarcoma" />
<input id="partner" name="partner" type="hidden" value="" />
<input id="tags" name="tags" type="hidden" value="sarcoma" />
<input id="return_url" name="return_url" type="hidden" value="/sarcoma/trials" />
<div class='controls request-button'>
<input class="btn btn-primary join-btn" name="commit" type="submit" value="Join Now" />
</div>
<div class='clearfix'></div>
</form>
</div>


<hr>
</div>


</div>
</div>
</div>
</div>
</div>
<div class='footer_background_container'>
<div class='footer_background'></div>
</div>
<div id='fat_footer'>
<div class='container'>
<footer class='row'>
<ul>
<li class='title'>
Links
</li>
<li>
<a href='../signin.html' title='Smart Patients - Home'>Conversations</a>
</li>
<li>
<a href='../stories.html' title='Stories'>Stories</a>
</li>
<li>
<a href='../quotes.html' title='Quotes recommended by members of the Smart Patients community.'>Quotes</a>
</li>
<li>
<a href='../trials.html' title='Search for clinical trials'>Clinical Trials</a>
</li>
</ul>
<ul>
<li class='title'>
Resources
</li>
<li>
<a href='../tutorial.html' title='Tutorial'>Tutorial</a>
</li>
<li>
<a href='../glossary.html' title='Tutorial'>Glossary</a>
</li>
<li>
<a href='../faq.html' title='Frequently asked questions'>FAQ</a>
</li>
</ul>
<ul>
<li class='title'>
Company
</li>
<li>
<a href='../about.html' title='About'>About</a>
</li>
<li>
<a href='../terms.html' title='Terms of Agreement'>Terms</a>
</li>
<li>
<a href='../privacy.html' title='Privacy Statement'>Privacy</a>
</li>
<li>
<a href='../contact.html' title='Contact Us'>Contact Us</a>
</li>
</ul>
<ul>
<li class='title'>
Social
</li>
<li>
<a href='../voices.html' title='Community Voices'>
<img alt="Icon_community_voices" src="../assets/icon_community_voices-51b928126bf735b2f04e9c969184afe3.png" />
Community Voices
</a>
</li>
<li>
<a href='../blog/index.html' title='Smart Patients Blog'>
<img alt="Icon_rss" src="../assets/icon_rss-16f5922fc759195730036b4454ef43a9.png" />
Smart Patients Blog
</a>
</li>
<li>
<a href='https://twitter.com/smart_patients' target='_blank' title='Twitter'>
<img alt="Icon_twitter" src="../assets/icon_twitter-5f7dbcc5d175199272b25b76fdda7dcd.png" />
Twitter
</a>
</li>
<li>
<a href='https://www.facebook.com/pages/Smart-Patients/393175704082838' target='_blank' title='Facebook'>
<img alt="Icon_facebook" src="../assets/icon_facebook-bb0ca36aa4757152d61004e0595d2e50.png" />
Facebook
</a>
</li>
</ul>
</footer>
<div class='copyright'>&copy;2015 Smart Patients, Inc., all rights reserved
</div>
<div class='creative_commons'>
<a href="../creative_commons.html">some icons</a>
are licensed under the Creative Commons license.
</div>
</div>
</div>

<script>
  var _gaq = _gaq || [];
  _gaq.push(['_setAccount', "UA-33347034-1"]);
  _gaq.push(['_setDomainName', 'smartpatients.com']);
  _gaq.push(['_trackPageview']);
  
  _gaq.push(['_setCustomVar',
    1,
    'logged_in',
    "false",
    2 // session-level
  ]);
  (function() {
    var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
    ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
  })();
</script>


<script src="../assets/application-6488ad0d66b77f64bcc10cde7b8e3212.js" type="text/javascript"></script>
<script src="../assets/jquery.hoverIntent.minified-3948fb0a36bb799e79553266985a1b22.js" type="text/javascript"></script>
<script src="../assets/jquery.validate.min-639617c1797dd4f18f2e40348e222928.js" type="text/javascript"></script>
<script src="../assets/jquery.cookie-108e498e814a1dbb62f1c6a88c61db48.js" type="text/javascript"></script>
<!--[if lt IE 10]>  <![endif]-->
<script src="../assets/jquery.placeholder.min-635ef1b648831ce3225097bb831210ca.js" type="text/javascript"></script>
<script>
  (function() {
    var root;
  
    root = typeof exports !== "undefined" && exports !== null ? exports : this;
  
    if ($('.wmd-input').length === 1) {
      root.converter = Markdown.getSanitizingConverter();
      root.converter.hooks.chain("preConversion", function(text) {
        text = text.replace(/^https?:\/\/[a-z0-9\.:]+(\/forums\/1-conversations\/topics\/[0-9]+-.*$)/mgi, "[Title of linked conversation will appear here]($1)");
        text = text.replace(/^(NCT[0-9]{8})$/mgi, "[Title for '$1' will appear here](/trials/$1)");
        text = text.replace(/:-\)/g, 'â˜º');
        text = text.replace(/:-\(/g, 'â˜¹');
        text = text.replace(/:flower:/g, 'âš˜');
        text = text.replace(/:heart:/g, 'â¤');
        text = text.replace(/:star:/g, 'â˜…');
        text = text.replace(/:rose:/g, 'â€');
        text = text.replace(/:music:/g, 'â™«');
        return text.replace(/(^|[\s\(])(NCT[0-9]{8})($|[\s\)])/gi, "$1[$2](/trials/$2)$3");
      });
      root.editor = new Markdown.Editor(converter);
      root.editor.run();
    }
  
  }).call(this);
</script>




</body>
</html>
